Document:

<PAGE>

                                                                   EXHIBIT 10.25

                    GENEEXPRESS(TM) PRODUCT ACCESS AGREEMENT

                                     BETWEEN

                                 GENE LOGIC INC.

                                       AND

                        GENAISSANCE PHARMACEUTICALS, INC.

                            DATED AS OF JUNE 28, 2000

<PAGE>

<TABLE>
<CAPTION>

                                TABLE OF CONTENTS                                                               PAGE

<S>      <C>                                                                                                     <C>
1.       DEFINITIONS..............................................................................................1
         1.1      "Access Term"...................................................................................1
         1.2      "Affiliate".....................................................................................1
         1.3      "Base Information"..............................................................................2
         1.4      "BioExpress(TM)Database"........................................................................2
         1.5      "cDNA"..........................................................................................2
         1.6      "Control".......................................................................................2
         1.7      "Delivery Plan".................................................................................2
         1.8      "Effective Date"................................................................................2
         1.9.     "Field".........................................................................................2
         1.10     "GeneExpress(TM)Product"........................................................................2
         1.11     "Gene Expression Information"...................................................................2
         1.12     "Genaissance Technology"........................................................................3
         1.13     "GeneExpress(TM)Data Warehouse".................................................................3
         1.14     "Gene Logic Software"...........................................................................3
         1.15     "Gene Logic Technology".........................................................................3
         1.16     "Gene Products".................................................................................3
         1.17     "Improvement"...................................................................................3
         1.18     "Isogenomics(TM)Database".......................................................................3
         1.19     "Patent Rights".................................................................................3
         1.20     "PharmExpress(TM)Database"......................................................................4
         1.21     "Program Invention".............................................................................4
         1.22     "SNP Data"......................................................................................4
         1.23     "ToxExpress(TM)Database"........................................................................4
         1.24     "Third Party"...................................................................................4

2.       ACCESS TO GENEEXPRESS(TM) PRODUCT, ANNOTATION OF GENEEXPRESS(TM) DATA  WAREHOUSE WITH SNP DATA,
         COMARKETING AND CUSTOM GENE EXPRESSION ANALYSIS..........................................................4
         2.1      Undertaking and Scope for Delivery Plan.........................................................4
         2.2      Personnel and Resources.........................................................................4

                                       i.
<PAGE>

<S>      <C>                                                                                                     <C>
         2.3      Internet Access.................................................................................4
         2.4      GeneExpress(TM)Updates..........................................................................4
         2.5      Support.........................................................................................5
         2.6      Training........................................................................................5
         2.7      Customization...................................................................................5
         2.8      Optional Onsite Installation....................................................................5
         2.9      Third Party Software............................................................................5
         2.10     SNP Annotation Plan.............................................................................5
         2.11     Co-Marketing Plan ..............................................................................5
         2.12     Custom Gene Analysis Service....................................................................6

3.       MANAGEMENT...............................................................................................6
         3.1      Program Directors...............................................................................6
         3.2      Dispute Resolution..............................................................................6

4.       INTELLECTUAL PROPERTY RIGHTS.............................................................................6
         4.1      Ownership of Inventions.........................................................................6
         4.2      Ownership of Gene Logic Technology..............................................................7
         4.3      Ownership of Genaissance Technology.............................................................7
         4.4      Pursuit of Intellectual Property Rights.........................................................7
         4.5      Cooperation and Communication...................................................................8
         4.6      Infringement by Third Parties...................................................................8
         4.7      Allegations of Infringement of Third Party Rights..............................................10

5.       LICENSES................................................................................................10
         5.1      Licenses to Gene Logic from Genaissance........................................................10
         5.2      GeneExpress(TM)Product Licenses to Genaissance from Gene Logic.................................10

6.       PAYMENTS................................................................................................11
         6.1      GeneExpress(TM)Product Access Fees.............................................................11

                                      ii.
<PAGE>
<S>      <C>                                                                                                     <C>
         6.2      Installation Fees..............................................................................11
         6.3      SNP Data Access Fees...........................................................................12
         6.4      Method of Payment..............................................................................12
         6.5      Method of Payment..............................................................................12

7.       CONFIDENTIALITY AND SECURITY............................................................................12

         7.1      Security of GeneExpress(TM)Product and Gene Logic Software.....................................12
         7.2      Confidentiality................................................................................13
         7.3      Permitted Disclosures..........................................................................13
         7.4      Publicity......................................................................................14
         7.5      Publication....................................................................................14
         7.6      Security of Genaissance's SNP Data and Tissue Samples..........................................14

8.       REPRESENTATIONS AND WARRANTIES..........................................................................15
         8.1      Legal Authority................................................................................15
         8.2      Valid Licenses.................................................................................15
         8.3      No Conflicts...................................................................................15
         8.4      SNP Data.......................................................................................15
         8.5      Representation by Legal Counsel................................................................15
         8.6      Disclaimer.....................................................................................15

9.       TERM AND TERMINATION....................................................................................16
         9.1      Term...........................................................................................16
         9.2      Termination for Breach.........................................................................16
         9.3      Early Termination by Genaissance...............................................................16
         9.4      Early Termination by Gene Logic................................................................17
         9.5      Effect of Bankruptcy...........................................................................17
         9.6      Remedies.......................................................................................18

                                      iii.
<PAGE>

<S>      <C>                                                                                                     <C>
10.      INDEMNIFICATION AND INSURANCE...........................................................................18
         10.1     Indemnification by Genaissance.................................................................18
         10.2     Indemnification by Gene Logic..................................................................18
         10.3     Conditions to Indemnification..................................................................18
         10.4     Settlements....................................................................................19

11.      GENERAL PROVISIONS......................................................................................19
         11.1     Assignment.....................................................................................19
         11.2     Non-Waiver.....................................................................................19
         11.3     Governing Law..................................................................................19
         11.4     Partial Invalidity.............................................................................19
         11.5     Notice.........................................................................................19
         11.6     Headings.......................................................................................20
         11.7     No Implied Licenses or Warranties..............................................................20
         11.8     Force Majeure..................................................................................20
         11.9     Survival.......................................................................................20
         11.10    Entire Agreement...............................................................................20
         11.11    Amendments.....................................................................................21
         11.12    Independent Contractors........................................................................21
         11.13    Counterparts...................................................................................21
</TABLE>

                                      iv.
<PAGE>

                                           COLLABORATION AGREEMENT

         THIS COLLABORATION AGREEMENT ("Agreement") is made as of June 28, 2000,
("Effective Date") by and between GENE LOGIC INC., a Delaware corporation ("Gene
Logic"), having an office at 708 Quince Orchard Road, Gaithersburg, Maryland
20878 and GENAISSANCE PHARMACEUTICALS INC., a Delaware corporation
("Genaissance"), having an office at Five Science Park, New Haven, CT 06511.
Gene Logic and Genaissance may each be referred to herein individually as a
"Party" and collectively as the "Parties."

                                   WITNESSETH:

         WHEREAS, Gene Logic has developed technologies and know-how with
respect to high throughput analysis of gene expression and gene regulation for
use in the identification of drug targets for the discovery of pharmaceutical
products;

         WHEREAS, Genaissance is a company engaged in commercializing population
genomics and informatics to improve development, marketing and prescription of
drugs and has developed high throughput capabilities for discovering Single
Nucleotide Polymorphisms (SNPs).

         WHEREAS, Gene Logic and Genaissance wish to enter into this Agreement
to, among other things, (i) provide Genaissance with non-exclusive access to the
BioExpress(TM), PharmExpress(TM) and ToxExpress(TM) portions of the
GeneExpress(TM) Data Warehouse and related software analysis tools for a period
of three (3) years, (ii) enhance the value and marketability of Gene Logic's
GeneExpress(TM) Data Warehouse to discovery scientists by annotating it with SNP
Data generated by Genaissance, (iii) enhance the value and marketability of
Genaissance's Isogenomics(TM) Database by annotating it with Gene Expression
Information from the GeneExpress(TM) Data Warehouse, and (iv) collaborate in
marketing each others products and services, each as more fully described
herein.

         NOW, THEREFORE, in consideration of the foregoing premises and the
mutual promises, covenants and conditions contained herein, Gene Logic and
Genaissance agree as follows:

1.       DEFINITIONS

         The following capitalized terms shall have the meanings indicated for
purposes of this Agreement:

         1.1 "ACCESS TERM" shall mean the period commencing on the Effective
Date and continuing until the third (3rd) anniversary of the Effective Date,
subject to termination as set forth herein.

         1.2 "AFFILIATE" shall mean any corporation, association or other entity
which directly or indirectly controls, is controlled by or is under common
control with the Party in question. As used in this definition of "Affiliate,"
the term "control" shall mean having the power to direct or cause the direction
of the management and policies of an entity, whether through direct or indirect
beneficial ownership of more than 50% of the voting or income interest in such

                                       1
<PAGE>

corporation or other business entity. Notwithstanding the foregoing, for
purposes of this Agreement, the term "Affiliate" shall not include subsidiaries
in which a Party or its Affiliates owns a majority of the ordinary voting power
to elect a majority of the board of directors but is restricted from electing
such majority by contract or otherwise, until such time as such restrictions are
no longer in effect.

         1.3 "BASE INFORMATION" shall mean data and information that resides in
the GeneExpress Data Warehouse comprising (i) gene expression profiles, (ii)
nucleotide sequence information, (iii) protein sequence information and (iv)
clinical and other information associated with tissue and cell samples; and any
related annotated information regarding, for example, the source of the
foregoing, their biological function(s), involvement in any metabolic or
regulatory pathway(s), relationship to any disease(s) or response to any
agent(s).

         1.4 "BIOEXPRESS(TM)" DATABase shall mean a database containing a subset
of the Base Information contained in the GeneExpress(TM) Data Warehouse derived
from untreated, (i) diseased and normal human tissues, (ii) research cell lines,
and (iii) animal model systems, such as, but not limited to, mouse and rat.

         1.5 "cDNA" shall mean a DNA copy of a mRNA, including, without
limitation, all cDNA clones and cDNA templates derived from a given gene
transcript and its corresponding coding sequence, including the full length
sequence.

         1.6 "CONTROL" shall mean possession of the ability to grant the
licenses or sublicenses or to make the assignments as provided for herein
without violating the terms of any agreement or other arrangement with any Third
Party.

         1.7 "DELIVERY PLAN" shall mean a plan developed by the Parties to allow
Genaissance to access the GeneExpress(TM) Product. The Delivery Plan will be
agreed to by the Parties after Gene Logic reviews the computer and
communications infrastructure of Genaissance.

         1.8 "EFFECTIVE DATE" shall mean the date of this Agreement first
written above.

         1.9 "FIELD" shall mean the use by Gene Logic of rights in Base
Information for (a) the sale or other commercial distribution of such Base
Information (e.g. databases of genomic and associated information) and (b) the
development and sale of prognostic and diagnostic products, including but not
limited to microarray-based products. The products described in (b) of this
Section 1.9 shall not include products which are claimed as a whole in Program
Inventions that are Controlled by Genaissance.

         1.10 "GENEEXPRESS(TM) PRODUCT" shall mean an information product which
consists of the BioExpress(TM) Database, ToxExpress(TM) Database,
PharmExpress(TM) Database and Gene Logic Software.

         1.11 "GENE EXPRESSION INFORMATION" shall mean information relating to
expression of genes in the Isogenomics(TM) Database that is derived and
reformatted by Genaissance from Base Information in the GeneExpress(TM) Data
Warehouse.

                                       2
<PAGE>

         1.12 "GENAISSANCE TECHNOLOGY" shall mean (a) all discoveries,
inventions, information, data, know-how, trade secrets and materials (whether or
not patentable) including tissue samples and SNP Data that are Controlled by
Genaissance as of the Effective Date or during the Access Term and are necessary
or useful to enable Gene Logic to perform its obligations under the Agreement,
(b) all Improvements thereto (regardless of which party makes such Improvements)
and (c) all Patent Rights or other intellectual property rights of Genaissance
covering the foregoing.

         1.13 "GENEEXPRESS(TM) DATA WAREHOUSE" shall mean a database containing
Base Information. The quantity of Base Information within the GeneExpress(TM)
Data Warehouse will increase over time.

         1.14 "GENE LOGIC SOFTWARE" shall mean software tools for the
visualization, analysis, indexing and mining of Base Information contained in
the GeneExpress(TM) Data Warehouse, to the extent that such software tools are
Controlled by Gene Logic as of the Effective Date or during the Access Term.

         1.15 "GENE LOGIC TECHNOLOGY" shall mean: (a) all discoveries,
inventions, information, data, know-how, trade secrets and materials (whether or
not patentable) that are Controlled by Gene Logic as of the Effective Date or at
any time during the Access Term that relate to: (i) methods and devices for
generating Base Information, (ii) the Gene Logic Software; (iii) the
GeneExpress(TM) Data Warehouse (other than the Base Information contained
therein); and (b) all Patent Rights or other intellectual property rights
Controlled by Gene Logic to the extent they cover any of the foregoing.

         1.16 "GENE PRODUCTS" shall mean tangible products derived from the use
of Base Information comprising (i) gene expression profiles, (ii) nucleotide
sequences including but not limited to all cDNAs, partial cDNAs, DNAs, genes,
corresponding full length cDNAs, (iii) proteins, (iv) methods of using the
foregoing based on their biological function(s), involvement in any metabolic or
regulatory pathway(s), relationship to any disease(s) or response to any
agent(s), and (v) commercial products which incorporate the foregoing.

         1.17 "IMPROVEMENT" shall mean any enhancement or improvement (whether
or not patentable) to any of the Gene Logic Technology or the Genaissance
Technology that is made by either Party: (i) in the course of performing its
respective obligations under the Delivery Plan; or (ii) while using the
BioExpress(TM) Product during the Access Term.

         1.18 "ISOGENOMICS(TM) DATABASE" shall mean Genaissance'S
ISOGENOMics(TM) Database containing annotated data on the identity, frequency
and distribution of SNPs generated by examining genomic DNA from Genaissance's
proprietary collection of immortalized cell lines established from unrelated
individuals from various geographical origins and from members of extended
families.

         1.19 "PATENT RIGHTS" shall mean all rights associated with all United
States and foreign patents (including all reissues, extensions, confirmations,
registrations, re-examinations, and inventor's certificates) and patent
applications (including, without limitation, all substitutions, continuations,
continuations-in-part and divisionals thereof).

                                       3
<PAGE>

                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         1.20 "PHARMEXPRESS(TM) DATABASE" shall mean a database ************* by
GeneLogic that will contain a subset of the Base Information contained in the
GeneExpress(TM) Data Warehouse associated with the treatment, using known drugs,
of (i) diseased and normal human tissues, (ii) research cell lines and (iii)
animal model systems, such as, but not limited to, mouse and rat.

         1.21 "PROGRAM INVENTIONS" shall mean any invention or discovery that is
or may be patentable under the laws of the United States, including but not
limited to Gene Products, and that is conceived or reduced to practice by either
Party from use of the GeneExpress(TM) Product during the Access Term.

         1.22 "SNP DATA" shall mean the total number of SNPs detected by
Genaissance in certain human genes. FOR THE AVOIDANCE OF DOUBT, SNP Data shall
not include the identity or position of any SNPs detected by Genaissance.

         1.23 "TOXEXPRESS(TM) DATABASE" shall mean a database containing a
subset of the Base Information contained in the GeneExpress(TM) Data Warehouse
derived from Affymetrix GeneChips(R) associated with the treatment, using known
toxic compounds, of (i) diseased and normal human tissues, (ii) research cell
lines and (iii) animal model systems, such as, but not limited to, mouse and
rat.

         1.24 "THIRD PARTY" shall mean any party other than Genaissance, Gene
Logic or their respective Affiliates.

2.       Access to GeneExpress(TM) Product, Annotation of GeneExpress(TM) Data
         Warehouse with SNP Data, Comarketing and Custom Gene Expression
         Analysis

         2.1 UNDERTAKING AND SCOPE FOR DELIVERY PLAN. Gene Logic and Genaissance
will conduct work in accordance with the Delivery Plan to deliver the
GeneExpress(TM) Product to Genaissance within thirty (30) days of the Effective
Date. Each of Gene Logic and Genaissance agree to use its commercially
reasonable efforts to perform the activities detailed in the Delivery Plan in a
professional and timely manner.

         2.2 PERSONNEL AND RESOURCES. During the Access Term, the Parties agree
to commit the personnel, consultants, facilities, expertise, technology and
other resources necessary to perform their respective obligations under the
Agreement.

         2.3 INTERNET ACCESS. It shall be Gene Logic's responsibility to acquire
and maintain, at its expense, any hardware which may need to be installed at one
or more of Gene Logic's facilities in connection with the use by Genaissance of
the GeneExpress(TM) Product via the Internet. Genaissance shall acquire and
maintain at its expense any hardware which may need to be installed at one or
more of Genaissance's facilities, (e.g., VPNs).

         2.4 GENEEXPRESS(TM) UPDATES. During the Access Term, Gene Logic will
update the data content in the GeneExpress(TM) Product
**************************** by updating the Base Information and any other data
and information contained therein.

                                       4
<PAGE>
                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         2.5 SUPPORT. During the Access Term, Gene Logic, at its expense, will
provide Genaissance: (a) any subsequent release or version of the Gene Logic
Software (including bug fixes, patches and maintenance releases) included in the
GeneExpress(TM) Product as Gene Logic makes such releases available to its other
customers; and (b) support and maintenance of Gene Logic Software included in
the GeneExpress(TM) Product through reasonable consultation via telephone, fax,
electronic mail or otherwise during Gene Logic's normal business hours (8:00
a.m. to 5:00 p.m. Eastern Time on regular U.S. business days, holidays excepted)
on specific problems that arise in the delivery and use of the GeneExpress(TM)
Product. Should Genaissance request on-site support or maintenance it will pay
Gene Logic's reasonable out-of-pocket expenses and a daily consultation fee of
************************ during the Access Term.

         2.6 TRAINING. Gene Logic will provide ************ of initial training
on the GeneExpress(TM) Product. The cost of subsequent training or the use of
the GeneExpress(TM) Product, other than for new releases of Gene Logic Software
will be the responsibility of Genaissance. Such costs will include out-of-pocket
expenses as well as Gene Logic's then standard training rates.

         2.7 CUSTOMIZATION. This Agreement does not obligate Gene Logic to
provide additional customization work beyond what is set forth in the Delivery
and/or Installation Plan. To the extent Genaissance desires Gene Logic to
perform additional customization work, the Parties agree to use good faith
efforts to negotiate the terms of such engagement pursuant to which Gene Logic
will be paid its commercially then standard development rates.

         2.8 OPTIONAL ON-SITE INSTALLATION. Genaissance may elect on-site
installation. Gene Logic will, within fifteen (15) days of notification by
Genaissance of such election, review the site and its computer and
communications infrastructure and, with the cooperation of Gensaissance, will
provide Genaissance with an Installation Plan (the "Installation Plan"). Gene
Logic will, upon Genaissance approval of the Installation Plan (such approval to
occur within three (3) business days of receipt by Genaissance of the
Installation Plan), implement the Installation Plan. The Installation Plan will
include a price and timeline for such installation.

         2.9 THIRD PARTY SOFTWARE. Third Party software that is both integral to
the GeneExpress(TM) Product and which may be necessary for the development of or
either Party's use of the GeneExpress(TM) Product or the Parties' performance of
their respective obligations under Agreement. The determination of such Third
Party software will be at the sole discretion of Genaissance.

         2.10 SNP ANNOTATION PLAN. Within thirty (30) days of the Effective Date
the Parties will meet and agree on a plan for annotating the GeneExpress(TM)
Data Warehouse with SNP Data (the "SNP Annotation Plan"). The Parties will then
implement the SNP Annotation Plan within thirty (30) days of reaching accord on
the SNP Annotation Plan. The number of genes for which SNP Data will be provided
and the schedule for when such SNP Data will be provided is enumerated in
Schedule 2.10.

         2.11 CO-MARKETING PLAN Within six months of executing this Agreement,
the parties will mutually agree upon a collaborative marketing scheme, which
shall include at least: (a) joint marketing tools, specifically including
identification of Gene Logic as the source of annotated

                                       5
<PAGE>

Gene Expression Information in the Isogenomics(TM) Database and identification
of Genaissance as the source of SNP Data in the GeneExpress(TM) Data Warehouse;
(b) a procedure to establish which party shall serve as `primary lead' when both
parties independently enter into discussions with the same potential customer;
and (c) financial incentives (e.g. royalties or `finder's fees'), if any, to be
provided when one party secures new business for the other party.

         2.12 CUSTOM GENE EXPRESSION ANALYSIS SERVICE When requested by
Genaissance. Gene Logic agrees to use its reasonable best efforts to conduct
gene expression analysis on up to ********** tissue samples during the Term with
the proviso that a maximum of ********** tissue samples will be analyzed during
the first eighteen (18) months of the Term. Gene Logic will incorporate the Base
Information resulting from such gene expression analysis, along with clinical
information provided by Genaissance, into the GeneExpress(TM) Data Warehouse,
and specifically into the GeneExpress(TM) Product. Genaissance agrees to provide
tissue samples which will pass GeneLogic's standard operating procedures (SOPs)
for quality control of tissue acquisitions and RNA isolation therefrom ("QC).
Such SOPs shall be attached to this Agreement as Schedule 2.12. Genaissance
further agrees to provide Gene Logic with any clinical information which is
available to Genaissance at the time the tissue samples are provided to Gene
Logic. During the Access Term, Gene Logic agrees to provide Genaissance with
access, through the GeneExpress(TM) Product, to Base Information derived from
gene expression analysis of any tissue sample(s) provided by Genaissance
pursuant to this Section 2.12 within one hundred fifty days from receipt of any
such sample(s) that pass QC.

3.       MANAGEMENT

         3.1 PROGRAM DIRECTORS. Each Party shall designate one of its employees
as a program director ("Program Director") to facilitate communications between
the Parties. Genaissance shall submit all customer service requests to Gene
Logic through Genaissance's Program Director or his designee.

         3.2 DISPUTE RESOLUTION. During the Access Term, any material disputes
or disagreements between Gene Logic and Genaissance arising hereunder will be
referred to the Program Directors. If the Program Directors are unable to
resolve such disputes or disagreements within thirty (30) days, or if the
dispute or disagreement arises after the Access Term, then such dispute or
disagreements will be referred to the Chief Executive Officer of Gene Logic and
the Chief Executive Officer of Genaissance or their designees for good faith
resolution for a period of ninety (90) days. If the parties are unable to
resolve their dispute or disagreement, either Party may pursue other legal or
equitable remedies which may be available.

4.       INTELLECTUAL PROPERTY RIGHTS

         4.1 OWNERSHIP OF INVENTIONS. The inventorship of any Program Invention
(whether or not patentable) shall be determined in accordance with United States
patent law. Except as otherwise provided in this Article 4, the ownership of any
Program Invention shall be determined in accordance with inventorship (i.e., a
Party shall solely own Program Inventions made solely by its or its Affiliates'
employees or agents and the Parties shall jointly own Program Inventions made
jointly by their or their Affiliates' respective employees or agents). For
purposes of this

                                       6
<PAGE>

Agreement, joint inventorship or joint ownership by a Third Party shall not
affect the designation of a Program Invention as owned solely or jointly by the
Parties.

         4.2 OWNERSHIP OF GENE LOGIC TECHNOLOGY. Gene Logic shall own all rights
to the Gene Logic Technology and Improvements thereof. Genaissance hereby
irrevocably assigns to Gene Logic all right, title and interest in and to
Improvements to the Gene Logic Technology, which Improvements are Controlled by
Genaissance, to the extent made by employees or agents of Genaissance. If
Genaissance has any rights that cannot be assigned to Gene Logic, Genaissance
waives the enforcement of such rights, and if Genaissance has any rights that
cannot be assigned or waived, Genaissance hereby grants to Gene Logic an
exclusive, irrevocable, perpetual, worldwide, fully-paid license, with right to
sublicense through multiple tiers of sublicense, to such rights.

         4.3 OWNERSHIP OF GENAISSANCE TECHNOLOGY. Genaissance shall own all
rights to the Genaissance Technology and Improvements thereto. Gene Logic hereby
irrevocably assigns to Genaissance all right, title and interest in and to
Improvements to the Genaissance Technology made by employees or agents of Gene
Logic or its Affiliates. If Gene Logic has any rights that cannot be assigned to
Genaissance, Gene Logic waives the enforcement of such rights, and if Gene Logic
has any rights that cannot be assigned or waived, Gene Logic hereby grants to
Genaissance an exclusive, irrevocable, perpetual, worldwide, fully-paid license,
with right to sublicense through multiple tiers of sublicense, to such rights.

4.4      PURSUIT OF INTELLECTUAL PROPERTY RIGHTS.

         (a) Gene Logic shall be responsible, in its sole discretion and at its
sole cost, for the filing, prosecution and maintenance of: (a) Patent Rights,
copyrights and other proprietary rights claiming or directed to Gene Logic
Technology and Improvements thereto; and (b) Program Inventions owned solely by
Gene Logic.

         (b) Genaissance shall be responsible, in its sole discretion and at its
sole cost, for the filing, prosecution and maintenance of: (a) Patent Rights,
copyrights and other proprietary rights claiming or directed to the Genaissance
Technology, and any Improvements to any of the foregoing; and (b) Program
Inventions owned solely by Genaissance.

         (c) With respect to any Program Invention that is owned jointly by the
Parties ("Joint Program Invention"), Gene Logic shall be responsible for
preparing, filing and prosecuting any patent applications or other appropriate
filings and maintaining any patents, copyrights or other similar rights issued
thereon, using patent counsel reasonably acceptable to Genaissance, and the
Parties shall share equally the out-of-pocket expenses for such preparation,
filing, prosecution and maintenance, including, without limitation, any
out-of-pocket expenses incurred, paid or reimbursed by a Party. Genaissance may,
at any time, by written notice to Gene Logic elect not to continue sharing such
expenses with respect to any Joint Program Invention, in which event,
Genaissance shall, upon the written request of Gene Logic, assign to Gene Logic
all of its right, title and interest in and to such Joint Program Invention.

                                       7
<PAGE>

4.5      COOPERATION AND COMMUNICATION.

         (a) COOPERATION. Each Party agrees to cooperate, both during and after
the Access Term, upon request of the other Party in the preparation and
prosecution of all Patent Rights claiming either Program Inventions or
Improvements and other proprietary rights directly relating to Program
Inventions or Improvements under this Article 4 and in the maintenance of any
patents, copyrights or other similar rights issued thereon; provided, however,
that, following the Access Term, the requesting Party shall reimburse the
cooperating Party for its reasonable out-of-pocket expenses incurred in
connection with such cooperation as requested by the other Party. Such
cooperation will include the execution of all documents necessary or desirable
for the requesting Party to fulfill its obligations hereunder.

         (b) COMMUNICATION REGARDING PATENT PROTECTION. Gene Logic will prepare,
prosecute and maintain and shall keep Genaissance currently informed of all
steps to be taken in the preparation, prosecution and maintenance of all Patent
Rights, copyrights or other similar rights related to Joint Program Inventions
and shall furnish Genaissance with copies of documentation of such Patent
Rights, copyrights or other similar rights and other related correspondence
relating thereto to and from governmental patent agencies or other authorities.

         (c) RELEASE OF RIGHTS. If Gene Logic with respect to any Joint Program
Invention decides to abandon or not to pursue prosecution or continue the
maintenance of any Patent Right, copyright or other proprietary right which
claims such Joint Program Invention, it shall permit Genaissance, at
Genaissance's option and expense, to undertake such obligations. Gene Logic
shall fully cooperate with Genaissance and shall provide to Genaissance whatever
assignments and other documents that may be needed in connection therewith.

4.6      INFRINGEMENT BY THIRD PARTIES.

         (a) INFRINGEMENT OF SOLELY OWNED PROGRAM INVENTIONS. If either Party
should become aware of any infringement or threatened infringement or
misappropriation, as the case may be, by a Third Party of any Patent Right
claiming a Program Invention solely owned by either Party and licensed to the
other Party hereunder it shall promptly notify the other Party in writing and
shall provide such other Party with all available evidence supporting such
allegation of infringement or threatened infringement or misappropriation. As
soon as practicable, the Parties shall confer on the particulars of such
infringement or misappropriation and the possible courses of action to be taken.
The Party holding the affected Patent Rights shall have the right, but not the
obligation, to institute, prosecute and control any legal proceedings in its own
name by its own counsel and at its own expense to prevent or restrain such
infringement, and shall be entitled to retain all costs and damages recovered
from such Third Party in such proceedings or by way of settlement. If, within
six (6) months of the date notice is provided in accordance with the first
sentence of this Section 4.6(a), such infringement or threatened infringement or
misappropriation continues and the Party holding the affected Patent Rights has
not initiated legal proceedings against the Third Party, the other Party shall
have the right, but not the obligation, to institute, prosecute and control
legal proceedings against such Third Party in its own name, by its own counsel
and at its own expense, to prevent or restrain such infringement unless
prevented from doing so by the laws of the country where the infringement or

                                       8
<PAGE>

misappropriation occurred or is threatened, and shall be entitled to retain all
damages and costs recovered from prosecuting such suit.

         (b) INFRINGEMENT OF JOINTLY OWNED PROGRAM INVENTIONS. If either Party
should become aware of any infringement or threatened infringement or
misappropriation, as the case may be, of any of the Patent Rights claiming a
Joint Program Invention, it shall promptly notify the other Party in writing and
shall provide such other Party with all available evidence supporting such
allegation of infringement or threatened infringement or misappropriation. As
soon as practicable the Parties shall confer on the particulars of such
infringement or misappropriation and the possible courses of action to be taken.
Gene Logic shall have the primary right and responsibility (but not the
obligation) to institute, prosecute, and control any action or proceeding with
respect to infringement or misappropriation of such Joint Patent Rights and
Genaissance shall have the right, at its expense (subject to reimbursement as
provided herein), to be represented by its counsel. In the event Gene Logic does
not institute or prosecute any such proceedings, Genaissance, shall at its
option and expense, be entitled to initiate or prosecute such proceedings. Each
Party hereby consents to the filing of any such action by the other Party with
respect to any such Joint Patent Rights in accordance with this Section 4.6(b).
If one Party brings any such action or proceeding, the other Party hereby
consents to being joined as a party plaintiff where necessary and, in case of
joining, such other Party agrees to give the first Party reasonable assistance
and authority to file and to prosecute such suit, at the expense of the Party
bringing such suit. If either Party prosecutes an infringement or
misappropriation of such Joint Patent Rights, any damages and costs recovered in
any proceedings or by way of settlement under this Section 4.6(b) shall be
shared by the Parties as follows:

            (i) the actual costs and expenses of all suits brought by either
Party under this Section 4.6(b) shall be reimbursed first to the filing Party
and then to the participating Party; and

            (ii) any remaining damages or other recoveries shall then be split
fifty percent (50%) to Gene Logic and fifty percent (50%) to Genaissance.

         (c) SETTLEMENTS. In connection with any proposed settlement in respect
of any infringement or threatened infringement of any Patent Rights owned solely
by the other Party or any Joint Patent Rights, the Party prosecuting such
infringement in accordance with this Section 4.6 and intending to settle shall
notify and consult with the other Party as to the terms of settlement, whose
written consent shall be required prior to any such settlement, such consent not
to be unreasonably withheld.

         (d) COOPERATION. In connection with any action taken by either Party
against a Third Party to protect or enforce any Patent Rights claiming Program
Inventions, the other Party shall, if requested, consult with the Party taking
such action, and make available as witnesses its employees or as evidence any
materials, and/or data as are reasonably necessary for the furtherance of such
action. The out of pocket expenses in connection with the providing of witnesses
and/or the making available of any materials and/or data shall be borne by the
Party taking action against the Third Party.

                                       9
<PAGE>

                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         4.7 ALLEGATIONS OF INFRINGEMENT OF THIRD PARTY RIGHTS.

         The Parties acknowledge that, in order to exploit the rights contained
herein, Genaissance may require licenses under Third Party patent rights that
may be infringed by the use by Genaissance of the rights granted herein (other
than the use of the Gene Logic Technology) and it is hereby agreed that it shall
be Genaissance's responsibility to satisfy itself as to the need for such
licenses (other than licenses to Third Party patent rights that are infringed by
the Gene Logic Technology) and, if necessary, to obtain such licenses.
Genaissance shall have no obligation to license or sublicense to Gene Logic any
such rights acquired from a Third Party (through license, purchase or
otherwise).

5.       LICENSES

         5.1 LICENSES TO GENE LOGIC FROM GENAISSANCE

            (a) GENAISSANCE TECHNOLOGY LICENSE. Subject to the terms and
conditions of this Agreement, Genaissance hereby grants to Gene Logic an
irrevocable, perpetual, non-transferable, non-exclusive, worldwide,
royalty-free license to the Genaissance Technology solely for annotating Base
Information in the GeneExpress(TM) Data Warehouse with SNP Data as described
in the SNP Annotation Plan. Gene Logic may ******************************
****************************************************************** to allow
such Third Parties to properly utilize the annotated Base Information. For
the avoidance of doubt, Gene Logic will not use the Genaissance Technology to
develop diagnostic or therapeutic products.

            (b) PROGRAM INVENTION LICENSE IN THE FIELD. Genaissance will
grant to Gene Logic a perpetual, worldwide, fully-paid non-exclusive license
to Program Inventions in the Field, **********************************, under
any patent rights or other rights Controlled by Genaissance.

            (c) LICENSE TO BASE INFORMATION FROM GENAISSANCE TISSUE SAMPLES.
Genaissance will grant to Gene Logic a perpetual, worldwide, fully-paid
non-exclusive license to use Base Information generated from Genaissance
tissue samples pursuant to Section 2.12 in the Field,
***************************************************, under any patent rights
or other rights Controlled by Genaissance.

         5.2 GENEEXPRESS(TM) PRODUCT LICENSES TO GENAISSANCE FROM GENE LOgic

            (a) Subject to the terms and conditions of this Agreement, including
without limitation payment of the Access Fees under Section 6.1, Gene Logic
hereby grants to Genaissance a*************************************************
*******************************************************************************

license to access the Base Information in the GeneExpress(TM) Product and to
use the Base Information in the GeneExpress(TM) Product during the Access Term,
or such longer period of time as may be agreed in writing by the Parties for
(i) annotating the Isogenomics(TM) Database with Gene Expression Information,
(ii) disclosing such annotated Isogenomics(TM) Database to third party
customers of Genaissance, and (iii) for performing pharmaceutical research and
development,

                                       10
<PAGE>

                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

including the selection of genes for further pharmacogenetic studies. FOR THE
AVOIDANCE OF DOUBT, Genaissance's use of Base Information will not include
incorporation into the Isogenomics(TM) Database of Base Information defined in
Sections 1.3(i), 1.3 (ii), and 1.3 (iii). In the event Genaissance elects to
have the GeneExpress(TM) Product installed on servers located at Genaissance's
facilities, then Genaissance shall also be entitled to exercise the rights
granted to it under this Section 5.2.

            (b) Except for disclosure to Genaissance's Affiliates and
Genaissance's and Genaissance's Affiliates' respective employees and consultants
to the extent permitted under Section 7.3, and except for disclosure of the
Isogenomics(TM) Database annotated with Gene Expression Information pursuant to
Section 5.2(a)(ii), Genaissance shall not provide Base Information contained
within the GeneExpress(TM) Product or the GeneExpress(TM) Data Warehouse or any
Gene Logic Technology or Improvement thereto to any Third Party without the
prior written consent of Gene Logic.

            (c) Should Genaissance wish to extend the term of its license to the
GeneExpress(TM) Product beyond the end of the Access Term, the extension of the
term of such license and the access fees payable for such extension will be
subject to mutual agreement by Gene Logic and Genaissance.

6.       PAYMENTS

         6.1 GENEEXPRESS(TM) PRODUCT ACCESS FEES. Annual GeneExpress(TM) Product
Fees will be paid by Genaissance to cover (i) the initial and ongoing access to
the GeneExpress(TM) Product via the internet, (ii) all GeneExpress(TM) Product
Data content updates and (iii) continuous upgrades and releases of Gene Logic
Software. The first annual GeneExpress(TM) Product fee shall be
***************************************************, the second annual
GeneExpress(TM) Product fee shall be **************************** and the third
annual GeneExpress(TM) Product fee shall be ******************************. The
annual GeneExpress(TM) Product fee for the first year of the Term will be
payable to Gene Logic as follows:

            (i)               ****************                   ********
            (ii)              ****************                   ********
            (iii)             *************                      *********
            (iv)              ***********                        *********

******************************************************************************
******************************************************************************
*********

         6.2 INSTALLATION FEES. Genaissance, at its option, may elect to have
the GeneExpress(TM) Product installed on servers located at Genaissance's
facilities as described in paragraph 2.8 for an additional installation fee as
set out in the Installation Plan. Such installation fee will be payable to Gene
Logic thirty (30) days after the installation is complete as described in the
Installation Plan.

                                       11
<PAGE>

                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         6.3 SNP DATA ACCESS FEES. Annual SNP Data Fees will be paid by Gene
Logic to cover (i) the initial and ongoing access to the SNP Data, and (ii) all
SNP Data content updates. The first annual SNP Data fee shall be
**************************, the second annual SNP Data fee shall be
************************** and the third annual SNP Data fee shall be ***
***********************. The annual SNP Data fee for the first year of the Term
will be paid to Genaissance as follows:

            (i)               ****************                   ********
            (ii)              ***************                    ********
            (iii)             *************                      *********
            (iv)              ***********                        *********

******************************************************************************
******************************************************************************

         6.4 METHOD OF PAYMENT. All payments to be made under this Agreement to
Genaissance shall be made in United States dollars in the United States to a
bank account designated by Genaissance by wire transfer pursuant to the
instructions set forth on Schedule 6.4.

         6.5 METHOD OF PAYMENT. All payments to be made under this Agreement to
Gene Logic shall be made in United States dollars in the United States to a bank
account designated by Gene Logic by wire transfer pursuant to the instructions
set forth on Schedule 6.5.

7.       CONFIDENTIALITY AND SECURITY

         7.1 SECURITY OF GENEEXPRESS(TM) PRODUCT AND GENE LOGIC SOFTWARE. The
Parties agree that the following additional terms and conditions apply to the
information and data contained in or derived from the GeneExpress(TM) Product
and Gene Logic Software provided under the provisions of this Agreement:

            (a) Except as specifically authorized herein, Genaissance may use
the GeneExpress(TM) Product and Gene Logic Software only for its own internal
business purposes in secure work facilities by authorized personnel and shall
not make any copies of the data contained in the GeneExpress(TM) Product.

            (b) Genaissance will promptly notify Gene Logic of any (i) loss,
theft or unauthorized disclosure of data contained in the GeneExpress(TM)
Product or the Gene Logic Software; and (ii) unauthorized access to the
GeneExpress(TM) Product upon becoming aware thereof.

            (c) Unless the term is extended, upon termination of the Access
Term, Genaissance shall immediately discontinue use of the GeneExpress(TM)
Product and Gene Logic Software and Genaissance shall (i) cooperate with Gene
Logic to terminate any encrypted link to Gene Logic's computer system and (ii)
promptly deliver to Gene Logic copies of any GeneExpress(TM) Product and Gene
Logic Software. Genaissance may, however, continue to use Gene Expression
Information as provided in Sections 5.2(a)(ii) and any results it generated from
use of the GeneExpress(TM) Product.

                                       12
<PAGE>

   7.2      CONFIDENTIALITY.

            (a) Except as specifically permitted hereunder, each Party hereby
agrees to hold in confidence and not use on behalf of itself or others all
technology, data, samples, technical and economic information (including the
economic terms hereof), commercialization, clinical and research strategies,
know-how and trade secrets provided by the other Party (the "Disclosing Party")
from the date of that certain confidentiality agreement between the Parties
dated April 11, 2000 and through the end of the Access Term and all data,
results and information developed pursuant to this Agreement that are solely
owned by the Disclosing Party or jointly owned by the parties (collectively the
"Confidential Information"), except that the term "Confidential Information"
shall not include:

               (i) information that is or becomes part of the public domain
other than through a breach of this Agreement by the non-Disclosing Party or its
Affiliates;

               (ii) information that is obtained after the Effective Date hereof
by the non-Disclosing Party or one of its Affiliates from any Third Party which
is lawfully in possession of such Confidential Information and not in violation
of any contractual or legal obligation to the Disclosing Party with respect to
such Confidential Information;

               (iii) information that was already known to the non-Disclosing
Party or one or more of its Affiliates prior to disclosure by the Disclosing
Party, as evidenced by the non-Disclosing Party's written records;

               (iv) information that is required to be disclosed to any
governmental authorities or pursuant to any regulatory filings, but only to the
limited extent of such legally required disclosure; and

               (v) information which has been independently developed by the
non-Disclosing Party without the aid or use of Confidential Information as shown
by competent written evidence.

            (b) The obligations of this Section 7.2 shall survive the expiration
or termination of this Agreement for a period of five (5) years.

    7.3     PERMITTED DISCLOSURES. Confidential Information may be disclosed to
employees, agents, consultants or sublicensees of the non-Disclosing Party or
its Affiliates, but only to the extent required to accomplish the purposes of
this Agreement and only if the non-Disclosing Party obtains prior agreement from
its employees, agents, consultants and sublicensees to whom disclosure is to be
made to hold in confidence and not make use of such information for any purpose
other than those permitted by this Agreement. Each Party will use at least the
same standard of care as it uses to protect proprietary or confidential
information of its own to ensure that such employees, agents, consultants and
sublicensees do not disclose or make any unauthorized use of the Confidential
Information. Notwithstanding any other provision of this Agreement, each Party
may disclose the terms of this Agreement to lenders, investment bankers and
other financial institutions of its choice solely for purposes of financing the
business operations of such Party either (i) upon the written consent of the
other Party or (ii) if the disclosing Party obtains a signed confidentiality
agreement with such financial

                                       13
<PAGE>

institution with respect to such information, upon terms substantially similar
to those contained in this Section 7. In addition, notwithstanding any other
provisions of this Agreement, nothing herein shall limit Gene Logic's ability to
grant non-exclusive access to the Base Information contained within the
GeneExpress(TM) Data Warehouse to multiple subscribers.

         7.4 PUBLICITY. The parties agree that a press release announcing the
matters covered by this Agreement will be prepared in advance and will be
subject to the mutual approval of the parties, which approval will not
unreasonably be withheld; provided, however, that either Party may (i) publicize
the existence and general subject matter of this Agreement consistent with
previous press releases and statements without the other Party's approval and
(ii) disclose the terms of this Agreement only to the extent required to comply
with applicable securities laws.

         7.5 PUBLICATION. The parties shall cooperate in appropriate publication
of the results of activities contemplated by this Agreement, but subject to the
predominating interest to obtain patent protection for any patentable subject
matter and to Gene Logic's business interest in preserving the value of the
GeneExpress(TM) Data Warehouse. To this end, prior to any public disclosure of
such results, the Party proposing disclosure shall send the other Party a copy
of the information to be disclosed, and shall allow the other Party thirty (30)
days from the date of receipt in which to determine whether the information to
be disclosed contains subject matter for which patent protection should be
sought prior to disclosure, otherwise contains Confidential Information of the
reviewing Party, or, with respect to any proposed disclosure by Genaissance,
contains information that Gene Logic reasonably believes would impair the value
of the GeneExpress(TM) Data Warehouse. The Party proposing disclosure shall be
free to proceed with the disclosure unless prior to the expiration of such
thirty (30) day period the non-disclosing Party notifies the other Party that
the disclosure contains subject matter for which patent protection should be
sought or Confidential Information of the non-disclosing Party or, if
Genaissance is the disclosing Party, Gene Logic notifies Genaissance that Gene
Logic reasonably believes that the disclosure would impair the value of the
GeneExpress(TM) Data Warehouse, and the Party proposing publication shall then
delay public disclosure of the information for an additional period of up to
three months to permit the preparation and filing of a patent application on the
subject matter to be disclosed or for the parties to determine a mutually
acceptable modification to such publication to protect the Confidential
Information of the non-disclosing Party adequately or to address Gene Logic's
concern regarding impairment of the value of the GeneExpress(TM) Data Warehouse.
The Party proposing disclosure shall thereafter be free to publish or disclose
the information. The determination of authorship for any paper shall be in
accordance with accepted scientific practice.

7.6      SECURITY OF GENAISSANCE'S SNP DATA AND TISSUE SAMPLES.

         (a) Gene Logic agrees to not transfer any tissue samples provided by
Genaissance pursuant to Section 2.12 to any third party, or identify Genaissance
as the source of any tissue samples from which Base Information has been
incorporated into any Gene Logic product, without prior written permission from
Genaissance.

         (b) Upon termination of the Access Term, Gene Logic shall promptly
return to Genaissance any unused tissue samples provided by Genaissance. Gene
Logic may, however,

                                       14
<PAGE>

continue to use the SNP Data and Base Information pursuant to the licenses
granted under Section 5.1.

8.       REPRESENTATIONS AND WARRANTIES

         8.1 LEGAL AUTHORITY. Each Party represents and warrants to the other
that (i) it is a corporation or entity duly organized and validly existing under
the laws of the state or other jurisdiction of incorporation or formation; (ii)
it has the legal power, authority and right to enter into this Agreement and to
perform its respective obligations set forth herein; and (iii) the execution,
delivery and performance of this Agreement by such Party has been duly
authorized by all requisite corporate officials and do not require any
shareholder action or other approval.

         8.2 VALID LICENSES. Each Party represents and warrants to the other
Party that it has authority to grant the rights and licenses set forth in this
Agreement.

         8.3 NO CONFLICTS. Each Party represents and warrants that as of the
Effective Date of this Agreement it is not a Party to any agreement or
arrangement with any Third Party or under any obligation or restriction,
including pursuant to its Certificate of Incorporation or Bylaws, which in any
way limits or conflicts with its ability to fulfill any of its obligations under
this Agreement.

         8.4 SNP DATA. Genaissance hereby represents and warrants that it has
the right to provide to Gene Logic SNP Data that are provided by Genaissance
hereunder.

         8.5 REPRESENTATION BY LEGAL COUNSEL. Each Party hereto represents that
it has been represented by legal counsel in connection with the drafting of this
Agreement and acknowledges that it has participated in the drafting hereof. In
interpreting and applying the terms and provisions of this Agreement, the
Parties agree that no presumption shall exist or be implied against the Party
that drafted such term or provision.

         8.6 DISCLAIMER. Except as expressly set forth in this Agreement, EACH
PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTAGBILITY OR FITNESS FOR A PARTICULAR PURPOSE (IN PARTICULAR WITH REGARD
TO THE GENEEXPRESS(TM) PRODUCT), OR THAT THE USE OF THE INFORMATION, MATERIALS,
SOFTWARE AND OTHER TECHNOLOGY PROVIDED HEREUNDER WILL NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF ANY THIRD PARTY. NEITHER PARTY MAKES
ANY WARRANTY OF ANY KIND AS TO THE PATENTABILITY OF ANY DISCOVERY MADE OR
TECHNOLOGY DEVELOPED UNDER THIS AGREEMENT. EACH PARTY ACKNOWLEDGES THAT THIS
AGREEMENT PROVIDES FOR AN INNOVATIVE PROGRAM UTILIZING NEW TECHNOLOGIES AND THAT
NO WARRANTY IS MADE AS TO THE UTILITY OF ANY INFORMATION, MATERIALS, SOFTWARE OR
OTHER TECHNOLOGY PROVIDED HEREUNDER.

                                       15
<PAGE>

9.       TERM AND TERMINATION

         9.1 TERM. Unless earlier terminated in accordance with this Article 9,
the term of this Agreement shall begin on the Effective Date and continue until
the expiration of the Access Term, or such longer period of time as the Parties
may agree in writing in accordance with Section 5.2(b)(iii) hereof. Should
Genaissance not terminate the Agreement before the end of the three (3) year
period described in paragraph 1.1, it may elect to extend the Access Term by up
to ninety (90) days by written request at no additional charge.

         9.2 TERMINATION FOR BREACH.

             (a) BREACH BY GENE LOGIC. If Gene Logic breaches a material term of
this Agreement at any time, and has not cured such breach within sixty (60) days
after written notice thereof from Genaissance, then Genaissance shall have the
right to terminate this Agreement effective upon written notice thereof,
whereupon all rights and obligations of the Parties under this Agreement shall
terminate except as set forth in Section 11.9 and subject to the following:
Genaissance shall have the fully paid up right and license to use, for any
purpose, all information, other than Base Information, obtained by Genaissance
through its use of the GeneExpress(TM) Product. FOR THE AVOIDANCE OF DOUBT,
Genaissance shall have the right to continue using and disclosing Gene
Expression Information pursuant to Sections 5.2(a) and 5.2(b).

             (b) BREACH BY GENAISSANCE. If Genaissance breaches a material term
of this Agreement at any time, and has not cured such breach within sixty (60)
days (or within thirty (30) days in the event of a material breach by
Genaissance of its obligations to make any payment due pursuant to Section 6.1)
after written notice thereof from Gene Logic, then Gene Logic shall have the
right to terminate this Agreement effective upon written notice thereof,
whereupon all rights and obligations of the Parties under this Agreement shall
terminate except as set forth in Section 11.9 and subject to the following: (i)
the rights granted to Genaissance pursuant to Sections 5.2 shall terminate, and
(ii) Genaissance shall return to Gene Logic all Confidential Information of Gene
Logic. FOR THE AVOIDANCE OF DOUBT, Gene Logic shall have the right to continue
using and disclosing SNP Data pursuant to Sections 5.1(a) and 5.1(b).

             (c) RESOLUTION OF DISPUTES. If a dispute arises between the Parties
relating to the grounds for the termination under this Section 9.2, the Parties
agree to hold a meeting, attended by individuals with decision-making authority,
to attempt in good faith to negotiate a resolution of the dispute. If, within
thirty (30) days after such meeting the Parties have not succeeded in
negotiating a resolution of the dispute, then the Parties may pursue any
available remedy, at law or in equity.

         9.3 EARLY TERMINATION BY GENAISSANCE. At eighteen (18) months from the
Effective Date (the "Early Termination Date"), Genaissance may terminate (i) its
obligation to pay the fees under paragraph 6.1 and (ii) its rights to access the
GeneExpress(TM) Product (notwithstanding this Section 9.3, all other rights and
obligations described in paragraph 11.9 and Genaissance's right to use and
disclose the Gene Expression Information under Sections 5.2(a) and 5.2(b) shall
survive such termination and remain in effect) without penalty only upon any one
of the following five (5) criteria being met:

                                       16
<PAGE>

                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         1)       **************************************************************
         ***********************************************************************
         ***********************************************************************
         ***********************************************************************
         ***********************************************************************
         ********************************

         2)       **************************************************************
         ****************************************************************

         3)       **************************************************************
         ********************************

         4)       **************************************************************
         ***********************************************************************
         **************

         5)       ********************************************************

         Genaissance shall exercise early termination pursuant to this Section
         9.3 by notifying Gene Logic by ten business days prior to the Early
         Termination Date. Genaissance may not terminate the Agreement before or
         after the Early Termination Date other than under Sections 9.2(a) and
         9.5.

         9.4 EARLY TERMINATION BY GENE LOGIC. At the "Early Termination Date",
Gene Logic may terminate its obligation to pay the fees under paragraph 6.2
(notwithstanding this paragraphs all other rights and obligations described in
paragraph 11.9 will survive such termination and remain in effect) without
penalty only upon any one of the following two (2) criteria being met:

         1)       *************************************************************
         ***********************************************************************
         ****

         2)       *********************************************************

Gene Logic shall exercise early termination pursuant to this Section 9.4 by
notifying Genaissance by ten business days prior to the Early Termination Date.
Gene Logic may not terminate the Agreement before or after the Early Termination
Date other than under Sections 9.2(b) and 9.5.

         9.5 EFFECT OF BANKRUPTCY. If, during the Access Term, either Party
files a voluntary petition in bankruptcy, is adjudicated a bankrupt, makes a
general assignment for the benefit of creditors, admits in writing that it is
insolvent or fails to discharge within sixty (60) days an involuntary petition
in bankruptcy filed against it, then this Agreement may be immediately
terminated by the other Party. In addition, in the event that Gene Logic files a
voluntary petition in bankruptcy, is adjudicated a bankrupt, makes a general
assignment for the benefit of creditors, admits in writing that it is insolvent
or fails to discharge within sixty (60) days an involuntary

                                       17
<PAGE>

petition in bankruptcy filed against it, then the parties hereby acknowledge and
agree that Genaissance will have right of access to the GeneExpress(TM) Data
Warehouse consistent with the terms of this Agreement for purposes of 11 U.S.C.
Section 365(n).

         9.6 REMEDIES. In the event of any breach of any provision of this
Agreement, in addition to the termination rights set forth herein, each Party
shall have all other rights and remedies at law or equity to enforce this
Agreement.

10.      INDEMNIFICATION AND INSURANCE

         10.1 INDEMNIFICATION BY GENAISSANCE. Genaissance shall indemnify,
defend and hold harmless Gene Logic and its Affiliates, and each of its and
their respective employees, officers, directors and agents (each, a "Gene Logic
Indemnified Party") from and against any and all liability, loss, damage, cost,
and expense (including reasonable attorneys' fees) (collectively, a "Liability")
which the Gene Logic Indemnified Party may incur, suffer or be required to pay
resulting from or arising in connection with any Third Party action or claim
based upon (i) the breach by Genaissance of any covenant, representation or
warranty contained in this Agreement, or (ii) the performance by Genaissance of
its obligations under the GeneExpress Product Delivery Plan. Notwithstanding the
foregoing, Genaissance shall have no obligation under this Agreement to
indemnify, defend or hold harmless any Gene Logic Indemnified Party with respect
to claims, demands, costs or judgments which result from annotation of the
GeneExpress(TM) Data Warehouse with SNP Data or from willful misconduct or
negligent acts or omissions of Gene Logic, its Affiliates, or any of their
respective employees, officers, directors or agents.

         10.2 INDEMNIFICATION BY GENE LOGIC. Gene Logic shall indemnify, defend
and hold harmless Genaissance and its Affiliates, and each of its and their
respective employees, officers, directors and agents (each, a "Genaissance
Indemnified Party") from and against any Liability which the Genaissance
Indemnified Party may incur, suffer or be required to pay resulting from or
arising in connection with any Third Party action or claim based upon (i) the
breach by Gene Logic of any covenant, representation or warranty contained in
this Agreement, or (ii) the performance by Gene Logic of its obligations under
the GeneExpress(TM) Product Delivery Plan. Notwithstanding the foregoing, Gene
Logic shall have no obligation under this Agreement to indemnify, defend, or
hold harmless any Genaissance Indemnified Party with respect to claims, demands,
costs or judgments which result from annotation of the Isogenomics(TM) Database
with Gene Expression Information or from willful misconduct or negligent acts or
omissions of Genaissance, its Affiliates, or any of their respective employees,
officers, directors or agents.

         10.3 CONDITIONS TO INDEMNIFICATION. The obligations of the indemnifying
Party under Sections 10.1 and 10.2 are conditioned upon the delivery of written
notice to the indemnifying Party of any potential Liability promptly after the
indemnified Party becomes aware of such potential Liability. The indemnifying
Party shall have the right to assume the defense of any suit or claim related to
the Liability if it has assumed responsibility for the suit or claim in writing;
however, if in the reasonable judgment of the indemnified Party, such suit or
claim involves an issue or matter which could have a materially adverse effect
on the business operations or assets of the indemnified Party, the indemnified
Party may waive its rights to indemnity under this Agreement and control the
defense or settlement thereof, but in no event shall any such waiver

                                       18
<PAGE>

be construed as a waiver of any indemnification rights such Party may have at
law or in equity. If the indemnifying Party defends the suit or claim, the
indemnified Party may participate in (but not control) the defense thereof at
its sole cost and expense.

         10.4 SETTLEMENTS. Neither Party may settle a claim or action related to
a Liability without the consent of the other Party, if such settlement would
impose any monetary obligation on the other Party or require the other Party to
submit to an injunction or otherwise limit the other its Affiliates, employees,
agents, officers and directors.

11.      GENERAL PROVISIONS

         11.1 ASSIGNMENT. This Agreement shall not be assignable by either Party
without the prior written consent of the other Party, such consent not to be
unreasonably withheld or delayed, except a Party may make such an assignment
without the other Party's consent to Affiliates or to a successor to
substantially all of the business of such Party, whether in merger, sale of
stock, sale of assets or other transaction; provided, however, that in the event
of such transaction, no intellectual property rights of any Affiliate or Third
Party that is an acquiring Party shall be included in the technology licensed
hereunder. This Agreement shall be binding upon and inure to the benefit of the
parties' successors, legal representatives and assigns. Notwithstanding the
foregoing, Genaissance and Gene Logic may not assign their respective rights
under the Agreement to any of the direct competitors enumerated in Schedule
11.1.

         11.2 NON-WAIVER. The waiver by either of the parties of any breach of
any provision hereof by the other Party shall not be construed to be a waiver of
any succeeding breach of such provision or a waiver of the provision itself.

         11.3 GOVERNING LAW. This Agreement shall be construed and interpreted
in accordance with the laws of the State of Delaware other than those provisions
governing conflicts of law.

         11.4 PARTIAL INVALIDITY. If and to the extent that any court or
tribunal of competent jurisdiction holds any of the terms or provisions of this
Agreement, or the application thereof to any circumstances, to be invalid or
unenforceable in a final nonappealable order, the parties shall use their best
efforts to reform the portions of this Agreement declared invalid to realize the
intent of the parties as fully as practicable, and the remainder of this
Agreement and the application of such invalid term or provision to circumstances
other than those as to which it is held invalid or unenforceable shall not be
affected thereby, and each of the remaining terms and provisions of this
Agreement shall remain valid and enforceable to the fullest extent of the law.

         11.5 NOTICE. Any notice to be given to a Party under or in connection
with this Agreement shall be in writing and shall be (i) personally delivered,
(ii) delivered by a nationally recognized overnight courier, (iii) delivered by
certified mail, postage prepaid, return receipt requested or (iv) delivered via
facsimile, with receipt confirmed, to the Party at the address set forth below
for such Party:

                                       19
<PAGE>

         To Genaissance:                       To Gene Logic:

         Five Science Park                     708 Quince Orchard Road
         New Haven, CT  06511                  Gaithersburg, Maryland  20878
         Attn:  Chief Financial Officer        Attn:  Chief Financial Officer
         Phone:  (203)-773-1450                Phone:  (301) 987-1700
         Fax:  (203)-562-9377                  Fax:  (301) 987-1701

         or to such other address as to which the Party has given written notice
thereof. Such notices shall be deemed given upon receipt.

         11.6 HEADINGS. The headings appearing herein have been inserted solely
for the convenience of the parties hereto and shall not affect the construction,
meaning or interpretation of this Agreement or any of its terms and conditions.

         11.7 NO IMPLIED LICENSES OR WARRANTIES. No right or license under any
patent application, issued patent, know-how or other proprietary information is
granted or shall be granted by implication. All such rights or licenses are or
shall be granted only as expressly provided in the terms of this Agreement.
Neither Party warrants that (i) the activities of the Parties hereunder shall
achieve any of the research objectives contemplated by them or (ii) any clinical
or other studies will be successful. The foregoing disclaimer shall not apply to
Gene Logic's obligation to conduct those analyses necessary to populate the
GeneExpress(TM) Product with Base Information.

         11.8 FORCE MAJEURE. Except for the obligation to make payment when due,
no failure or omission by the parties hereto in the performance of any
obligation of this Agreement shall be deemed a breach of this Agreement nor
shall it create any liability if the same shall arise from any cause or causes
beyond the reasonable control of the affected Party, including, but not limited
to, the following, which for purposes of this Agreement shall be regarded as
beyond the control of the Party in question: acts of nature; acts or omissions
of any government; any rules, regulations, or orders issued by any governmental
authority or by any officer, department, agency or instrumentality thereof;
fire; storm; flood; earthquake; plague of epic proportion; accident; war;
rebellion; insurrection; riot; invasion; strikes; and labor lockouts; provided
that the Party so affected shall use its best efforts to avoid or remove such
causes of nonperformance and shall continue performance hereunder with the
utmost dispatch whenever such causes are removed.

         11.9 SURVIVAL. Sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.6(b), (c) and (d),
5.1, 5.2(a)(ii), 5.2(b) 7.2, 7.3, 7.6, 8, 9 (including the provisions therein
that are contemplated to continue following termination), 10, 11.3, 11.4, 11.6,
11.9, 11.10 and 11.13 shall survive the termination or expiration of this
Agreement.

         11.10 ENTIRE AGREEMENT. This Agreement, including the exhibits and
schedules hereto, constitutes the entire understanding between the parties with
respect to the subject matter contained herein and supersedes any and all prior
agreements, understandings and arrangements whether oral or written between the
parties relating to the subject matter hereof; PROVIDED, HOWEVER, that the
provisions of the Prior Agreement that are expressly contemplated to continue

                                       20
<PAGE>

following termination shall not be superseded hereby and shall continue in force
in accordance with their terms. Notwithstanding the foregoing, this Agreement
does not supercede or void in any way any obligations of either Party under the
Prior Agreement.

         11.11 AMENDMENTS. No amendment, change, modification or alteration of
the terms and conditions of this Agreement shall be binding upon either Party
unless in writing and signed by the Party to be charged.

         11.12 INDEPENDENT CONTRACTORS. It is understood that both parties
hereto are independent contractors and are engaged in the operation of their own
respective businesses, and neither Party hereto is to be considered the agent of
the other Party for any purpose whatsoever. Neither Party has any authority to
enter into any contracts or assume any obligations for the other Party or make
any warranties or representations on behalf of the other Party.

         COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument. IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be executed by their duly
authorized officers as of the date first above written.

GENE LOGIC INC.                               GENAISSANCE PHARMACEUTICALS, INC.

By:             /s/ Mark Gessler             By: /s/ Kevin Rakin
  -----------------------------------          -------------------------------
     Mark Gessler                             Kevin Rakin
     Chief Executive Officer                  Executive Vice President and
                                              Chief Financial Officer

                                       21
<PAGE>

                                  SCHEDULE 1.19

                      GENEEXPRESS(TM) PRODUCT DELIVERY Plan

      [To be provided by Gene Logic upon site and IT infrastructure review]

<PAGE>

                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                  SCHEDULE 2.10

                                SNP DATA FORECAST

                 DATE                               NUMBER OF GENES
                 ***************                    ****
                 ***************                    ****
                 *************                      ****
                 ************                       ****
                 ***************                    ****
                 ***************                    ****
                 *************                      ****
                 ************                       ****
                 ***************                    ****
                 ***************                    ****
                 *************                      ****
                 *************                      ****

<PAGE>

                                  SCHEDULE 2.12

                STANDARD OPERATING PROCEDURES FOR QUALITY CONTROL

[To be provided by Gene Logic within ten business days after the Effective Date]

<PAGE>

                                  SCHEDULE 6.4

                 GENAISSANCE WIRE TRANSFER PAYMENT INSTRUCTIONS

    Bank:                                      State Street Bank
    Location:                                  225 Franklin Street
                                               Boston, MA  02110
    ABA #:                                     011000028
    For further credit to client funds #:      DE0590
    Account Name:                              GENAISSANCE PHARMACEUTICALS, INC.
    Account #:                                 17039843
<PAGE>
                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                  SCHEDULE 6.5

                  GENE LOGIC WIRE TRANSFER PAYMENT INSTRUCTIONS

      Bank:                                    ******************************
      Location:                                *************

                                               *****************
      ABA #:                                   *********
      For further credit to client funds #:    *********
      Account Name:                            ***************
      Account #:                               *****

<PAGE>
                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                  SCHEDULE 9.3

                              GXDB CONTENT FORECAST

               SAMPLE*                         TOTAL NUMBER OF SAMPLES
                                              (NORMAL & DISEASE RELATED)

        *********************                            ***
                *****                                    ***
                ****                                     ***
               ******                                    ***
                *****                                     **

   *Samples consist of human tissue, associated animal models and cell lines.

<PAGE>
                    *CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE
            SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                  SCHEDULE 11.1

                               LIST OF COMPETITORS

                                   **********

                                     ******

                                     *******

                                     ******

                              *********************

                                      *****

                             **********************

                                   **********

                                    *********

                                     ******

                                  *************

                                      ****

                                     *******

                                    ********

                                   ***********<PAGE>

                              AMENDED AND RESTATED
                          REGISTRATION RIGHTS AGREEMENT

         This AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this
"AGREEMENT") is made as of the 10th day of March, 2000, by and between
GENAISSANCE PHARMACEUTICALS, INC., a Delaware corporation (the "CORPORATION"),
and the parties signatory hereto.

         WHEREAS, the Corporation and each of the parties identified on SCHEDULE
I hereto (each an "INVESTOR") are parties to a certain Stock Purchase Agreement,
dated as of February 17, 2000 (as amended from time to time, the "SERIES B/KBH
STOCK PURCHASE AGREEMENT"), by and between the Corporation and the Investors,
pursuant to which the Investors have purchased shares of the Series B
Convertible Preferred Stock, $.001 par value, of the Corporation (the "SERIES
B") or shares of the Series KBH Nonvoting Convertible Preferred Stock, $.001 par
value, of the Corporation (the "SERIES KBH"); and

         WHEREAS, under certain circumstances, shares of the Series B may be
converted into shares of the Series B1 Convertible Preferred Stock, $.001 par
value, of the Corporation (the "SERIES B1"), and shares of the Series KBH may be
converted into shares of the Series KBH1 Nonvoting Convertible Preferred Stock,
$.001 par value, of the Corporation (the "SERIES KBH1"); and

         WHEREAS, in connection with the Series B/KBH Stock Purchase Agreement,
the Corporation and the Investors entered into a certain Registration Rights
Agreement, dated as of February 17, 2000 (as amended, the "ORIGINAL SERIES B/KBH
REGISTRATION RIGHTS AGREEMENT"), which provides, among other things, for the
registration of the shares purchased under the Series B/KBH Stock Purchase
Agreement; and

         WHEREAS, concurrent with the effectiveness of this Agreement, the
Corporation will become a party to a certain Stock Purchase Agreement, dated as
of the date hereof (as amended from time to time, the "SERIES C STOCK PURCHASE
AGREEMENT") by and between the Corporation and certain purchasers of the
Corporation's Series C Convertible Preferred Stock, $.001 par value (the "SERIES
C"); and

         WHEREAS, under certain circumstances, shares of the Series C may be
converted into shares of the Series C1 Convertible Preferred Stock, $.001 par
value, of the Corporation (the "SERIES C1"); and

         WHEREAS, in connection with the Series C Stock Purchase Agreement, the
Corporation will also become a party to a certain Registration Rights Agreement,
dated as of the date hereof (as amended from time to time, the "SERIES C
REGISTRATION RIGHTS AGREEMENT") by and between the Corporation and the
purchasers of the Series C; and

         WHEREAS, concurrent with the effectiveness of this Agreement, the
Corporation will also become a party to a certain Second Amended and Restated
Registration Rights Agreement, dated as of the date hereof (as amended from time
to time, the "SECOND AMENDED AND RESTATED

<PAGE>

SERIES A/KBL REGISTRATION RIGHTS AGREEMENT") by and between the Corporation and
certain purchasers of the Corporation's Series A Redeemable Convertible
Preferred Stock, $.001 par value (the "SERIES A") and Series KBL Nonvoting
Redeemable Convertible Preferred Stock, $.001 par value (the "SERIES KBL"); and

         WHEREAS, under certain circumstances, shares of the Series A may be
converted into shares of the Series A1 Redeemable Convertible Preferred Stock,
$.001 par value, of the Corporation (the "SERIES A1"), and shares of the Series
KBL may be converted into shares of the Series KBL1 Nonvoting Redeemable
Convertible Preferred Stock, $.001 par value, of the Corporation (the "SERIES
KBL1"); and

         WHEREAS, in connection with, and so as to facilitate the consummation
of, the transactions contemplated by the Series C Stock Purchase Agreement, the
Corporation and the other parties hereto desire to amend and restate the
Original Series B/KBH Registration Rights Agreement in the manner set forth
herein; and

         WHEREAS, the registration rights of the holders of the Series B/KBH
Preferred Stock under this Agreement, as amended and restated hereby, are
intended to be PARI PASSU with the registration rights of the holders of the
Series C Preferred Stock under the Series C Registration Rights Agreement.

         NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

         1.       DEFINITIONS. As used in this Agreement, the following terms
shall have the following respective meanings:

         "COMMISSION" shall mean the Securities and Exchange Commission or any
other Federal agency at the time administering the Securities Act.

         "COMMON STOCK" shall refer to both the voting common stock of the
Corporation, par value $.001 per share, and the nonvoting common stock of the
corporation, par value $.001 per share.

         "OTHER SHARES" shall mean all shares of Common Stock other than (i)
Restricted Securities, (ii) Series A Common Stock and (iii) shares to be issued
by the Corporation proposed to be included in a registration of shares of Common
Stock of the Corporation under the Securities Act as described in this
Agreement.

         "PERSON" shall mean and include an individual, a corporation, a
partnership, a trust, an unincorporated organization and a government or any
department, agency or political subdivision thereof.

         "PREFERRED STOCK" shall mean and include the Series B/KBH Preferred
Stock and the Series C Preferred Stock.

                                      -2-
<PAGE>

         "PRIOR WARRANTS" shall refer to (i) that certain Warrant, dated
December 20, 1996, in the name of Technology Investment Fund Incorporated, to
purchase an aggregate of 41,800 shares of Common Stock; (ii) that certain
Warrant, dated November 4, 1998, in the name of Finova Technology Finance, to
purchase 26,250 shares of Common Stock; and (iii) that certain Warrant, dated
April 30, 1999, in the name of TBCC Funding Trust II, to purchase 50,000 shares
of Common Stock.

         "PRIOR WARRANT SHARES" shall refer to the shares of Common Stock that
are issuable upon exercise of the Prior Warrants.

         "RESERVED SHARES" shall mean all shares of Common Stock of the
Corporation issuable or issued upon conversion of any of the shares of Preferred
Stock, and any shares of capital stock of the Corporation received in respect
thereof, whether by reason of a stock split, stock dividend, share
reclassification or other similar event.

         "RESTRICTED SECURITIES" shall mean (i) the Preferred Stock, (ii) the
Reserved Shares and (iii) any shares of capital stock of the Corporation
received in respect thereof, whether by reason of a stock split or share
reclassification thereof, a stock dividend thereon or otherwise, in each case
which have not been sold to the public pursuant to (a) a registration under the
Securities Act or (b) Rule 144 (or any similar or successor rule) promulgated
under the Securities Act subsequent to the Corporation's initial public offering
of securities registered under the Securities Act.

         "SECURITIES ACT" shall mean the Securities Act of 1933, as amended, or
any successor statute, and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.

         "SERIES A COMMON STOCK" shall mean shares of Common Stock of the
Corporation registerable pursuant to the Second Amended and Restated Series
A/KBL Registration Rights Agreement.

         "SERIES B/KBH PREFERRED STOCK" shall mean and include all shares of the
Series B, the Series B1, the Series KBH and the Series KBH1, and shares of any
additional series or subseries of the Series B or the Series KBH created
pursuant to Section 9 of the Certificate of Designations, Preferences and other
Special Rights and Qualifications, Limitations and Restrictions of the Series B,
Series B1, Series KBH and Series KBH1 filed with the Delaware Secretary of the
State under Section 242 of the General Corporation Law of the State of Delaware.

         "SERIES C PREFERRED STOCK" shall mean and include all shares of the
Series C, the Series C1, and shares of any additional series or subseries of the
Series C created pursuant to Section 9 of the Certificate of Designations,
Preferences and other Special Rights and Qualifications, Limitations and
Restrictions of the Series C and Series C1 filed with the Delaware Secretary of
the State under Section 242 of the General Corporation Law of the State of
Delaware.

                                      -3-
<PAGE>

         "TRANSFER" shall include any disposition of any Restricted Securities
or any interest therein which would constitute a sale within the meaning of the
Securities Act.

         2.       RESTRICTION ON TRANSFER. The Restricted Securities covered by
this Agreement shall not be transferable except upon the conditions specified in
this Agreement (which conditions are intended to ensure compliance with the
provisions of the Securities Act in respect of the transfer of such securities),
and the Amended and Restated Stockholders' Agreement, dated as of February 17,
2000 (as amended from time to time, the "STOCKHOLDERS' AGREEMENT"), among the
Corporation, the holders of its Series A, Series KBL, Series B, Series KBH, AND
Series C, Gualberto Ruano and Kevin Rakin.

         3.       RESTRICTIVE LEGENDS. Each certificate for Restricted
Securities covered by this Agreement, and each certificate for any such
securities issued to subsequent transferees of any such certificate, shall
(unless otherwise permitted by the provisions of this Agreement) be stamped or
otherwise imprinted with legends in substantially the following form:

                  THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN
                  ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE
                  SECURITIES ACT OF 1933. THESE SECURITIES MAY NOT BE SOLD OR
                  TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN
                  EXEMPTION THEREFROM UNDER SAID ACT.

         4.       NOTICE OF TRANSFER. The holder of any Restricted Securities
covered by this Agreement, by acceptance of such Restricted Securities, agrees,
prior to any Transfer of any such Restricted Securities, to give written notice
to the Corporation of such holder's intention to effect such Transfer and agrees
to comply in all other respects with the provisions of this Agreement. Each such
notice shall describe the manner and circumstances of the proposed Transfer and
shall be accompanied by the written opinion, addressed to the Corporation, of
counsel for the holder of such securities (which counsel shall be acceptable to
the Corporation), as to whether, in the opinion of such counsel, such proposed
Transfer involves a transaction requiring registration of such Restricted
Securities under the Securities Act; PROVIDED, HOWEVER, that no such opinion
shall be required (i) in connection with a Transfer pursuant to Section 5 or 6
hereof; (ii) in connection with a transaction complying with the requirements of
Rule 144 or Rule 144A (in each case as amended from time to time) promulgated
under the Securities Act (or successor rules thereto); or (iii) in connection
with a Transfer (A) to an affiliate (as defined in the Securities Act) of the
transferor or (B) by a holder which is a partnership, limited liability company
or corporation, to a partner, member/manager or shareholder, respectively, of
such holder or a retired partner, member/manager or shareholder, respectively,
of such holder who retires after the date hereof, or the estate of any such
partner, member/manager or shareholder or retired partner, retired
member/manager or retired shareholder or to a trust for the benefit of its
partners, retired partners and/or former partners or member/managers, retired
member/managers and/or former member/managers or shareholders, retired
shareholders and/or former shareholders; PROVIDED FURTHER, HOWEVER, that in the
case of clause (iii) above, the transferee represents and warrants to the
Corporation in writing that it is acquiring such Restricted Securities for its
own account for

                                      -4-
<PAGE>

investment and not with a view to the distribution thereof and agrees in writing
to be subject to the terms of this Agreement to the same extent as if such
transferee were an original signatory to this Agreement.

         Upon receipt by the Corporation of any such notice and other documents,
the following provision shall apply:

         (i)      If the proposed transfer of such Restricted Securities may be
         effected without registration of such Securities under the Securities
         Act, the holder of such securities shall thereupon be entitled to
         transfer such securities in accordance with the terms of the notice
         delivered by it to the Corporation. Each certificate or other
         instrument evidencing the securities issued upon the Transfer of any
         such securities (and each certificate or other instrument evidencing
         any untransferred balance of such securities) shall bear the legends
         set forth in Section 3 unless (A) in such opinion of such counsel, if
         required as set forth above, registration of future Transfer is not
         required by the applicable provisions of the Securities Act or (B) the
         Corporation shall have waived the requirement of such legends;
         PROVIDED, HOWEVER, that such legend shall not be required (i) on any
         certificate or other instrument evidencing the securities issued upon
         such Transfer in the event such Transfer shall be made in compliance
         with the requirements of Rule 144 (as amended from time to time)
         promulgated under the Securities Act (or any similar or successor Rule
         thereto), (ii) on any certificate or other instrument which is
         immediately resalable under Rule 144(k) (or any similar or successor
         Rule thereto), or (iii) in connection with a Transfer pursuant to
         Section 5 or 6 hereof;

         (ii)     If the proposed transfer of such Restricted Securities may not
         be effected without registration of such Securities under the
         Securities Act, the holder of such Securities shall thereupon not be
         entitled to transfer such securities until registration of the
         Restricted Securities involved in the above-mentioned request has
         become effective under the Securities Act.

         5.       REQUIRED REGISTRATION. If at any time, the Corporation shall
be requested by the holders of more than fifty percent (50%) of all Restricted
Securities at the time outstanding to effect the registration under the
Securities Act of the Reserved Shares, (assuming the conversion of all Preferred
Stock) the Corporation shall promptly give written notice of such proposed
registration to all holders of outstanding Restricted Securities, and thereupon
the Corporation shall promptly use its best efforts to effect the registration
under the Securities Act of the Reserved Shares which the Corporation has been
requested to register for disposition described in the request of said holder or
holders and in any response received within 45 days after the giving of the
written notice by the Corporation; PROVIDED, HOWEVER, that:

         (i)      The Corporation shall not be obligated to file and use its
         best efforts to cause to become effective any registration statement on
         or before the earlier of (a) February 1, 2001 or (b) 180 days after the
         consummation of a public offering of shares of Common Stock for cash
         registered under the Securities Act but excluding the registration of
         equity securities issued or issuable pursuant to any employee stock
         options, stock purchasers,

                                      -5-
<PAGE>

         stock bonus or similar plan or pursuant to a merger, exchange offer or
         transactions of the type specified in paragraph (a) of Rule 145 under
         the Securities Act.

         (ii)     The Corporation shall not be obligated to file and use its
         best efforts to cause to become effective more than two registration
         statements in which Reserved Shares are registered under the Securities
         Act pursuant to this Section 5 (or Section 5 of the Series C
         Registration Rights Agreement); PROVIDED, HOWEVER, that if Form S-3 is
         available to the Corporation for the registration of such Reserved
         Shares, the holders of such Reserved Shares shall be entitled to an
         unlimited number of such registrations on Form S-3 (provided that the
         aggregate amount of the proceeds of any such S-3 offering is at least
         $1,500,000);

         (iii)    Anything contained herein to the contrary notwithstanding,
         with respect to each registration requested pursuant to this Section 5
         (or Section 5 of the Series C Registration Rights Agreement), the
         Corporation may include in such registration any authorized but
         unissued shares of Common Stock for sale by the Corporation or any
         issued and outstanding shares of Common Stock for sale by others;
         PROVIDED, HOWEVER, that if the number of shares of Common Stock so
         included pursuant to this clause (iii) exceeds the number of shares
         registered by the holder or holders of outstanding Reserved Shares
         requesting such registration, then such registration shall be deemed to
         be a registration in accordance with and pursuant to Section 6 of this
         Agreement (or Section 6 of the Series C Registration Rights Agreement,
         as the case may be) and shall not count against the limit in Section
         5(ii) of this Agreement (or Section 5(ii) of the Series C Registration
         Rights Agreement, as the case may be); PROVIDED FURTHER, HOWEVER, that
         the inclusion of such previously authorized but unissued shares by the
         Corporation or issued and outstanding shares of Common Stock by others
         in such registration shall not prevent the holders of outstanding
         Restricted Securities requesting such registration from registering the
         entire number of Reserved Shares requested by them and, in the event
         the registration is, in whole or in part, an underwritten public
         offering and the managing underwriter determines and advises in writing
         that the inclusion of all Reserved Shares proposed to be included in
         such registration and such previously authorized but unissued shares of
         Common Stock by the Corporation and/or issued and outstanding shares of
         Common Stock by persons other than the holders of Restricted Securities
         proposed to be included in such registration would interfere with the
         successful marketing (including pricing) of such securities, then such
         other previously authorized but unissued shares of Common Stock
         proposed to be included by the Corporation and issued and outstanding
         shares of Common Stock proposed to be included by persons other than
         the holders of Restricted Securities shall be reduced or excluded from
         such registration (as the case may be); PROVIDED, HOWEVER, that this
         Section shall not be construed so as to require the exclusion of any
         Prior Warrant Shares from any offering if such exclusion would conflict
         with the terms of the Prior Warrants. If the inclusion of all such
         Reserved Shares would still nevertheless so interfere with the
         successful marketing of such securities, then the number of shares to
         be registered shall be reduced PRO RATA among the holders of the
         Reserved Shares; PROVIDED, HOWEVER, that if the amount of Reserved
         Shares is reduced by

                                      -6-
<PAGE>

         more than 25%, then such offering shall not count against the limit in
         Section 5(ii) (or Section 5(ii) of the Series C Registration Rights
         Agreement, as the case may be); and

         (iv)     For purposes of clarity, the parties acknowledge and agree
         that Section 5(ii) of this Agreement and Section 5(ii) of the Series C
         Registration Rights Agreement are intended to provide the holders of
         the Restricted Securities with a total of two demand registrations (not
         two demand registrations under this Agreement and two demand
         registrations under the C Registration Rights Agreement for a total of
         four demand registrations).

         6.       INCIDENTAL REGISTRATION. If the Corporation at any time
proposes for any reason to register any of its securities under the Securities
Act (other than on Forms S-4 or S-8 or any similar or successor form), other
than pursuant to Section 5 hereof (or Section 5 of the Series C Registration
Rights Agreement), it shall each such time promptly give written notice to all
holders of outstanding Restricted Securities of its intention so to do, and,
upon the written request, given within 30 days after receipt of any such notice,
of any holder or holders of the Restricted Securities then outstanding to
register any Reserved Shares (which request shall specify the Reserved Shares
intended to be sold or disposed of by such holders and shall state the intended
method of disposition of such Reserved Shares by the prospective seller), the
Corporation shall use its best efforts to cause all such Reserved Shares to be
registered under the Securities Act promptly upon receipt of the written request
of such holders for such registration, all to the extent requisite to permit the
sale or other disposition (in accordance with the intended methods thereof, as
aforesaid) by the prospective seller or sellers of the Reserved Shares so
registered. In the event that the proposed registration by the Corporation is,
in whole or in part, an underwritten public offering of securities of the
Corporation, any request pursuant to this Section 6 (or Section 6 of the Series
C Registration Rights Agreement, as the case may be) to register Reserved Shares
shall specify that such shares are to be included in the underwriting (a) on the
same terms and conditions as the shares of Common Stock, if any, otherwise being
sold through underwriters under such registration or (b) on terms and conditions
comparable to those normally applicable to offerings of Common Stock in
reasonably similar circumstances in the event that no other shares of Common
Stock are being sold through underwriters under such registration; PROVIDED,
HOWEVER, that if the managing underwriter determines and advises in writing that
the inclusion of all shares requested to be included in such registration would
interfere with the successful marketing (including pricing) of such securities,
then the number of Other Shares, shares of Series A Common Stock and such
Reserved Shares to be included in the underwritten public offering shall be
reduced, first among the holders of Other Shares on a pro rata basis, second
among the holders of the Series A Common Stock on a pro rata basis, and third
among the holders of the Reserved Shares on a pro rata basis; PROVIDED, HOWEVER,
that in no event shall the amount of Reserved Shares included in the offering be
reduced below 25% of the total amount of the securities included in such
offering (unless such offering is the initial public offering of the Company's
securities in which case the Reserved Shares may be reduced to zero); and
PROVIDED, FURTHER, HOWEVER, that this Section shall not be construed so as to
require the exclusion of any Prior Warrant Shares from any offering if such
exclusion would conflict with the terms of the Prior Warrants. Any Reserved
Shares which are excluded from the Corporation's initial public offering (either
because such shares were not requested by the

                                      -7-
<PAGE>

holders thereof to be included therein or which were excluded pursuant to the
immediately preceding sentence or in connection with a registration pursuant to
Section 5 hereof (or Section 5 of the Series C Registration Rights Agreement, as
the case may be) shall be withheld from the market by the holder thereof for a
period, not to exceed 180 days, which the managing underwriter reasonably
determines as necessary in order to effect the initial public offering.

         7.       PREPARATION AND FILING. If and whenever the Corporation is
under an obligation pursuant to the provisions of this Agreement (or the Series
C Registration Rights Agreement, as the case may be) to use its best efforts to
effect the registration of any Reserved Shares, the Corporation shall, as
expeditiously as practicable:

         (a)      prepare and file with the Commission a registration statement
         with respect to such Reserved Shares and use its best efforts to cause
         such registration statement to become and remain effective for at least
         180 days or until the selling stockholders have completed the
         distribution described in the registration statement relating thereto,
         whichever first occurs;

         (b)      prepare and file with the Commission such amendments and
         supplements to such registration statements and the prospectus used in
         connection therewith as may be necessary to keep such registration
         statement effective for at least the time period set forth in
         subsection (a) and to comply with the provisions of the Securities Act
         with respect to the sale or other disposition of all Reserved Shares
         covered by such registration statement;

         (c)      furnish to each selling stockholder such number of copies of a
         summary prospectus or other prospectus, including a preliminary
         prospectus, in conformity with the requirements of the Securities Act,
         and such other documents as such seller may reasonably request in order
         to facilitate the public sale or other disposition of such Reserved
         Shares;

         (d)      use its best efforts to register or qualify the Reserved
         Shares covered by such registration statement under the securities or
         blue sky laws of such jurisdictions as each such seller (or, in the
         case of an underwritten offering, the managing underwriter) shall
         reasonably request (PROVIDED, HOWEVER, that the Corporation shall not
         be required to consent to general service of process for all purposes
         in any jurisdiction where it is not then qualified, unless the
         Corporation is already subject to such service in such jurisdiction and
         except as may be required by the Securities Act);

         (e)      notify each seller of Reserved Shares covered by such
         registration statement, at any time when a prospectus relating to the
         Reserved Shares covered by such registration statement is required to
         be delivered under the Securities Act within the appropriate period
         mentioned in clause (b) of this Section 7, of the happening of any
         event as a result of which the prospectus included in such registration
         statement, as then in effect, includes an untrue statement of a
         material fact or omits to state a material fact required to be stated
         therein or necessary to make the statements therein not misleading in
         the light of the circumstances then existing, and at the request of
         such seller, prepare and furnish to such

                                      -8-
<PAGE>

         seller a reasonable number of copies of a supplement to or an amendment
         of such prospectus as may be necessary so that, as thereafter delivered
         to the purchasers of such shares, such prospectus shall not include an
         untrue statement of a material fact or omit to state a material fact
         required to be stated therein or necessary to make the statements
         therein not misleading in the light of the circumstances then existing;

         (f)      at the request of any holder or holders requesting
         registration of Reserved Shares pursuant to this Agreement (or the
         Series C Registration Rights Agreement, as the case may be), if such
         Reserved Shares are being sold through underwriters, furnish to the
         underwriters on the date that such Reserved Shares are delivered to the
         underwriters for sale, or, if such Reserved Shares are not being sold
         through underwriters, furnish to such holder or holders on the date
         that the registration statement with respect to such Reserved Shares
         becomes effective, (i) an opinion, dated such date, of the counsel
         representing the Corporation for the purposes of such registration, in
         form and substance as is customarily given to underwriters in an
         underwritten public offering, addressed to the underwriters, if any,
         and to the holder or holders making such request; and (ii) a letter
         dated such date, from the independent certified public accountants of
         the Corporation, in form and substance as is customarily given by
         independent certified public accountants to underwriters in an
         underwritten public offering, addressed to the underwriters, if any,
         and to the holder or holders making such request;

         (g)      cause all securities registered under this Agreement (or the
         Series C Registration Rights Agreement, as the case may be) to be
         listed on each securities exchange on which similar securities issued
         by the Corporation are then listed; and

         (h)      provide a transfer agent and registrar for all securities
         registered under this Agreement (or the Series C Registration Rights
         Agreement, as the case may be) and a cusip number not later than the
         effective date of such registration.

         8.       EXPENSES. All expenses incurred by the Corporation in
complying with Section 7, including, without limitation, all registration and
filing fees (including all expenses incident to filing with the National
Association of Securities Dealers, Inc.), fees and expenses of complying with
securities and blue sky laws, printing expenses and fees and disbursements of
counsel including with respect to each registration effected pursuant to
Sections 5 and 6, reasonable fees and disbursements of not more than one counsel
for the sellers requesting registration, and of the independent certified public
accountants for the Corporation (including the expense of any special audits in
connection with any such registration) shall be paid by the Corporation;
PROVIDED, HOWEVER, that all underwriting discounts and selling commissions
applicable to the Reserved Shares covered by such registration shall be borne by
the seller or sellers, in proportion to the number of Reserved Shares sold by
such seller or sellers.

         9.       INDEMNIFICATION. In connection with any registration of any
Reserved Shares under the Securities Act pursuant to this Agreement, the
Corporation shall indemnify and hold harmless the seller of such Reserved
Shares, each underwriter, broker or any other person acting on behalf of such
seller and each other person, if any, who controls any of the foregoing persons

                                      -9-
<PAGE>

within the meaning of the Securities Act against any losses, claims, damages or
liabilities, joint or several (or actions in respect thereof), to which any of
the foregoing persons may become subject under the Securities Act or otherwise
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon an untrue statement or alleged untrue
statement of a material fact contained in the registration statement under which
such Reserved Shares were registered under the Securities Act, any preliminary
prospectus or final prospectus contained therein or otherwise filed with the
Commission, any amendment or supplement thereto or any document incident to
registration or qualification of any Reserved Shares, or arise out of or are
based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading or, with respect to any prospectus, necessary to make the statements
therein in light of the circumstances under which they were made not misleading,
or any violation by the Corporation of the Securities Act or state securities or
blue sky laws applicable to the Corporation and relating to action or inaction
required of the Corporation in connection with such registration or
qualification under such state securities or blue sky laws; and shall reimburse
such seller, such underwriter, such broker or such other person acting on behalf
of such seller and each such controlling person for any legal or other expenses
reasonably incurred by any of them in connection with investigating or defending
any such loss, claim, damage, liability or action; PROVIDED, HOWEVER, that the
Corporation shall not be liable in any such case to the extent that any such
loss, claim, damage, liability or action arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged omission
made in said registration statement, preliminary prospectus, final prospectus,
amendment, supplement or document incident to registration or qualification of
any Reserved Shares in reliance upon and in conformity with written information
furnished to the Corporation by such seller or underwriter specifically for use
in the preparation thereof.

         In connection with any registration of Reserved Shares under the
Securities Act pursuant to this Agreement, each seller of Reserved Shares shall
indemnify and hold harmless (in the same manner and to the same extent as set
forth in the preceding paragraph of this Section 9) the Corporation and each
officer and director of the Corporation who shall sign such registration
statement, each underwriter, broker or other person acting on behalf of such
seller, each person who controls any of the foregoing within the meaning of the
Securities Act and each other seller of Reserved Shares under such registration
statement with respect to any statement in or omission from such registration
statement, any preliminary prospectus or final prospectus contained therein or
otherwise filed with the commission, any amendment or supplement thereto or any
document incident to registration or qualification of any Reserved Shares, if
such statement or omission was made in reliance upon and in conformity with
written information furnished by such Seller to the Corporation or such
underwriter specifically for use in connection with the preparation of such
registration statement, preliminary prospectus, final prospectus, amendment,
supplement or document or any failure by such Seller to deliver any registration
statement, preliminary prospectus, final prospectus, amendment, supplement or
document; PROVIDED, HOWEVER, that the maximum amount of liability in respect of
such indemnification (including, but not limited to, attorneys' fees and
expenses) shall be limited, in the case of each seller of Reserved Shares, to an
amount equal to the LESSER of:

                                      -10-

<PAGE>

         (A)      the amount of the loss, claim, damage or liability for which
         such seller is required hereunder to indemnify all parties, multiplied
         by a fraction, the numerator of which is the public offering price of
         the Reserved Shares sold by such seller under such registration
         statement and the denominator of which is the total public offering
         price of all securities sold under such registration statement; or

         (B)      the net proceeds actually received by such seller from the
         sale of Reserved Shares under such registration statement.

         Promptly after receipt by an indemnified party of notice of the
commencement of any action involving a claim referred to in the preceding
paragraphs of this Section 9, such indemnified party will, if a claim in respect
thereof is made against an indemnifying party, give written notice to the latter
of the commencement of such action. In case any such action is brought against
an indemnified party, the indemnifying party will be entitled to participate in
and to assume the defense thereof, jointly with any other indemnifying party
similarly notified to the extent that it may wish, with counsel reasonably
satisfactory to such indemnified party, and after notice from the indemnifying
party to such indemnified party of its election so to assume the defense
thereof, the indemnifying party shall not be responsible for any legal or other
expenses subsequently incurred by the indemnified party in connection with the
defense thereof, PROVIDED, HOWEVER, that if any indemnified party shall have
reasonably concluded that there may be one or more legal or equitable defenses
available to such indemnified party which are additional to or conflict with
those available to the indemnifying party, or that such claim or litigation
involves or could have an effect upon matters beyond the scope of the indemnity
agreement provided in this Section 9, the indemnifying party shall not have the
right to assume the defense of such action on behalf of such indemnified party
and such indemnifying party shall reimburse such indemnified party and any
person controlling such indemnified party for that portion of the reasonable
fees and expenses of any counsel retained by the indemnified party which is
reasonably related to the matters covered by the indemnity agreement provided in
this Section 9.

         10.      REMOVAL OF LEGENDS; ETC. Notwithstanding the foregoing
provisions of this Agreement, the restrictions imposed by this Agreement upon
the transferability of any Restricted Securities covered by this Agreement shall
cease and terminate when any such Restricted Securities are sold or otherwise
disposed of in accordance with the intended method of disposition by the seller
or sellers thereof set forth in an effective registration statement or as
otherwise contemplated by Section 4 hereof. Whenever the restrictions imposed by
this Agreement shall terminate, as herein provided, the holder of any Restricted
Securities covered by this Agreement shall be entitled to receive from the
Corporation, without expense, a new certificate not bearing the restrictive
legends set forth in Section 3 and not containing any other reference to the
restrictions imposed by this Agreement.

         11.      INFORMATION BY HOLDER. Each holder of Reserved Shares included
in any registration effected pursuant to this Agreement shall furnish to the
Corporation such information with respect to such holder and the proposed
distribution by such holder as the Corporation shall request in writing on a
timely basis and as shall, in the reasonable opinion of counsel for the

                                      -11-
<PAGE>

Corporation, be required by Federal or applicable state securities laws in
connection with such registration effected pursuant to this Agreement.

         12.      SECURITIES ACT REGISTRATION STATEMENTS. The Corporation shall
not file any registration statement (other than on Form S-4, Form S-8 or any
similar or successor form thereto) under the Securities Act covering any
securities unless it shall first have given each Investor written notice
thereof. The Corporation further covenants that each Investor shall have the
right, at any time when in its sole and exclusive judgment exercised in good
faith it is or might be deemed to be a controlling person of the Corporation, to
participate in the preparation of such registration statement and to require the
insertion therein of material furnished to the Corporation in writing, which in
such Investor's judgment or, if requested by the Corporation, in the opinion of
counsel to each Investor experienced in securities matters and acceptable to the
Corporation should be included.

         13.      SUCCESSORS AND ASSIGNS. The terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties (including transferees of any shares of
the Preferred Stock or any Common Stock of the Corporation issued upon
conversion thereof). Notwithstanding the foregoing, no registration rights shall
be exercisable with respect to any share after such share has been sold pursuant
to a registration statement declared effective under the Securities Act. Nothing
in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement.

         14.      GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with (a) the laws of the State of Connecticut as applied
to agreements entered into and to be performed entirely therein and (b) the laws
of the State of Delaware applicable to corporations organized under the laws of
such state.

         15.      COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         16.      NOTICES. All notices required or permitted to be given under
this Agreement shall be in writing. Notices may be given by certified or
registered mail, postage paid with return receipt requested; by private courier,
prepaid and with required signature; or personally, with signature required. All
notices shall be deemed delivered upon actual receipt. Notices shall be
delivered as set forth below:

         (i)               if to the Corporation, to:
                           Genaissance Pharmaceuticals, Inc.
                           Five Science Park
                           New Haven, CT 06511
                           Attn: President

                                      -12-
<PAGE>

                  with a copy to:

                           Robinson & Cole LLP
                           One Commercial Plaza
                           280 Trumbull Street
                           Hartford, CT 06103-3597
                           Attn:    Alan Spier, Esq.

         (ii)     if to any Investor, at their respective addresses set forth in
the Share Register (as such term is defined in the Series B/KBH Stock Purchase
Agreement) with copies as set forth in the Share Register.

         Each party to this Agreement agrees to provide prompt written notice to
the Corporation (addressed as set forth above and to the attention of the
Secretary of the Corporation) in the event that there shall occur any change in
the information contained in the Share Register with respect to such party
(including any change relating to the name, address, fax number, copy
information and shareholdings of such party).

         17.      AMENDMENTS AND WAIVERS. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or
prospectively), only with the written consent of the Corporation and the holders
of a majority of the Restricted Securities; PROVIDED, HOWEVER, that no amendment
or waiver which adversely affects the interests of one holder without a similar
and proportionate effect on the interest of all holders may be made without the
consent of the holder whose interests are so adversely affected. Any amendment
or waiver effected in accordance with this paragraph shall be binding upon each
existing holder of Restricted Securities, each future holder of such securities,
and the Corporation, PROVIDED, HOWEVER, that such amendment or waiver shall
affect all beneficiaries of the rights granted hereunder equally.

         18.      OTHER AGREEMENTS. Other than the Series B Stock Purchase
Agreement, the Stockholders' Agreement, and the Series C Registration Rights
Agreement, each party hereby represents that it is not a party to any other
agreement with any other party with respect to the subject matter hereof and
that this Agreement contains all of such party's understanding and agreement
concerning such subject matter. Further, the Corporation hereby agrees that it
will not enter into any other agreement with respect to the subject matter
hereof which grants rights superior to those granted to the Investors herein.

         19.      RESERVED.

         20.      LIMITATIONS ON SUBSEQUENT REGISTRATION RIGHTS. Without
limiting the provisions of Section 18 hereof, and except to the extent provided
in the Series C Registration Rights Agreement, from and after the date of this
Agreement, the Corporation shall not, without the prior written consent of the
holders of a majority of the outstanding Restricted Securities, enter into any
agreement with any holder or prospective holder of any securities of the
Corporation which would allow such holder or prospective holder (i) to include
such securities in any registration filed under Section 5 hereof, unless under
the terms of such agreement, such

                                      -13-
<PAGE>

holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of his securities will not
reduce the amount of the Reserved Shares of the holders which is included, or
(ii) to make a demand registration which could result in such registration
statement being declared effective prior to the earlier of February 1, 2001 or
within one hundred eighty (180) days of the effective date of any registration
effected pursuant to Section 5 of this Agreement (or Section 5 of the Series C
Registration Rights Agreement, as the case may be).

                                      -14-
<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                      GENAISSANCE
                                      PHARMACEUTICALS, INC.

                                      By  /s/ Gualberto Ruano
                                          -------------------
                                      Name:
                                      Its:

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                      A&A GENVEST LLP

                                      By  /s/ Ian Lambert and Ian Gibb
                                          ----------------------------
                                      Name: Ian Lambert and Ian Gibb
                                      Its:  Director and Alternate Director

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                      ABOVE VC CONSULTING

                                      By  s/s Jacy Cheng
                                          --------------
                                      Name:  Jacy Cheng
                                      Its:  President

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                      ALTA BIOPHARMA PARTNERS, L.P.

                                      By:  ALTA BIOPHARMA
                                      MANAGEMENT, LLC

                                      By  /s/ Daniel Janney
                                          -----------------
                                      Name:  Daniel Janney
                                      Its:

                                      ALTA EMBARCADERO BIOPHARMA,
                                      LLC

                                      By  /s/ Eileen McCarthy
                                          -------------------
                                      Name:  Eileen McCarthy
                                      Its:

                                      GENAISSANCE CHASE PARTNERS
                                      (ALTA BIO), LLC

                                      By:  ALTA/CHASE BIOPHARMA
                                      MANAGEMENT, LLC

                                      By  /s/ Daniel Janney
                                          -----------------
                                      Name:  Daniel Janney
                                      Its:

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                       ATLANTIC COASTAL VENTURES

                                       By  /s/ Donald F. Greene
                                           --------------------
                                       Name:  Donald F. Greene
                                       Its:  General Partner
         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                       CANAAN EQUITY II L.P.

                                       By:  CANAAN EQUITY PARTNERS II LLC

                                       By  /s/ Guy Russo
                                           -------------
                                       Name:  Guy Russo
                                       Its:

                                       CANAAN EQUITY II L.P. (QP)

                                       By:  CANAAN EQUITY LLC

                                       By  /s/ Guy Russo
                                           -------------
                                       Name:  Guy Russo
                                       Its:

                                       CANAAN EQUITY II ENTREPRENEUERS LLC

                                       By:  CANAAN EQUITY PARTNERS II LLC

                                       By  /s/ Guy Russo
                                           -------------
                                       Name:  Guy Russo
                                       Its:

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                       CHAO-FENG VENTURE CAPITAL
                                       CORPORATION

                                       By  /s/ Richard Chen
                                         ----------------
                                       Name:  Richard Chen
                                       Its: President

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                       CONNECTICUT INNOVATIONS, INC.

                                       By  /s/ Victor Budnick
                                           ------------------
                                       Name:  Victor Budnick
                                       Its:  President & Executive Director

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                       FAT VENTURE CAPITAL CO., LTD

                                       By /s/ Shahn-Jehn Guo
                                          ---------------------
                                       Name:  Shahn-Jehn Guo
                                       Its:

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          HUA-CHENG VENTURE CAPITAL
                                          CORPORATION

                                          By  /s/ Richard Chen
                                              ----------------
                                          Name:  Richard Chen
                                          Its: President

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          HUA-JING VENTURE CAPITAL
                                          CORPORATION

                                          By  /s/ Richard Chen
                                              ----------------
                                          Name:  Richard Chen
                                          Its: President

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          INTERNATIONAL BM BIOMEDICINE
                                          HOLDINGS INC.

                                          By  /s/ Stefan Ryser
                                              ----------------
                                          Name:  Stefan Ryser
                                          Its:  Managing Partner

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                           KLEINWORT BENSON HOLDINGS, INC.

                                           By  /s/ John Walker
                                               ---------------
                                           Name:  John Walker
                                           Its:  SVP & Director

                                           By  /s/ Frank Harte
                                               ---------------
                                           Name:  Frank Harte
                                           Its: SVP

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          MERIFIN CAPITAL N.V.

                                          By  /s/ Guillaume deRham
                                              --------------------
                                          Name:  Guillaume deRham
                                          Its: Director

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          MESBIC VENTURES, INC.

                                          By  /s/ Divakar Karnath
                                              -------------------
                                          Name:  Divakar Karnath
                                          Its:  Executive Vice President

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          OPPORTUNITY CAPITAL PARTNERS II, L.P.

                                          By /s/ J. Peter Thompson
                                             ----------------------
                                          Name:
                                          Its:

                                          OPPORTUNITY CAPITAL PARTNERS III, L.P.

                                          By /s/ J. Peter Thompson
                                             ----------------------
                                          Name:
                                          Its:

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          PACESETTER GROWTH FUND, L.P.

                                          By  /s/ Divakar Karnath
                                              -------------------
                                          Name:  Divakar Karnath
                                          Its:  Managing Director

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          SOFINOV SOCIETE FINANCIERE
                                          D'INNOVATION INC.

                                          By /s/ Denis Dionne
                                             ---------------------
                                          Name:
                                          Its:

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          WINCHESTER CAPITAL HEALTHCARE
                                          PARTNERS LLC

                                          By /s/ Caesar Anquillare
                                             ----------------------
                                          Name: Caesar Anquillare
                                          Its: President

<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Amended and Restated
Registration Rights Agreement to be duly executed and delivered as of the day
and year first written above.

                                          /s/ Seth Rudnick
                                          ----------------
                                          Seth Rudnick

<PAGE>

                                   SCHEDULE I

                         LIST OF SERIES B/KBH INVESTORS

See SCHEDULE I, as amended, to the Series B/KBH Stock Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]